Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lens esOver One Week of 
Wear
Protocol CR-6478
Version: 1.0
Date: 15December 2021
Investigational Products: Alcon PRECISION1®for Astigmatism Daily Contact Lenses, 
CooperVision MyDay®Toric Soft Contact Lenses
Keywords: Astigmatism, Alcon PRECISION1®for Astigmatism ,CooperVision MyDay®
Toric, verofilcon A ,stenfilcon A ,daily wear, daily disposable, dispensing, Single use Eye -
Cept®Rewetting Drops, LacriPure Sa line Solution, ScleralFil Pr eservative Free Saline 
Solution, CLUE comfort, CLUE vision, CLUE  handling, logMAR visual acuity, rotation 
performance .
Statement of Compliance to protocol, GCP and applicable regulatory guidelines:
This trial will be conducted in compliance with the proto col, ISO 14155 :2020 ,1the 
International Council for Harmonization Good Clinical Practice E6 (R2) (ICH GCP) ,2the 
Declaration of Helsinki ,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confident ial information, which should not be copied, referred to, 
released or published without written approval from Johnson & Johnson Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional 
Review Board/Independent Ethics Committee a pproval and informed consent, or as required 
by International, Federal and State Laws, as applicable. Pers ons to whom this information is 
disclosed must be informed that this informatio n is privileged and confidential and that it 
should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprieta ry to Johnson & Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document.
CR-6478, v1.0 
Page 1 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE ................................ ...................... 6 
SPONSOR NAME AND ADDRESS ................................ ................................ ....................... 6 
MEDICAL MONITOR ................................ ................................ ................................ ............. 6 
AUTHORIZED SIGNATURES ................................ ................................ ............................... 7 
CHANGE HISTORY ................................ ................................ ................................ ................ 8 
SYNOPSIS ................................ ................................ ................................ ................................ 9 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS
................................ ................................ ................................ ................................ ................. 15 
1. INTRODUCTION AND BACKGROUND ................................ ................................ ...16 
1.1. Name and Descriptions of Investigational Products ................................ ................ 16 
1.2. Intended Use of Investigational Products ................................ ................................ .16 
1.3. Summary of Findings from Nonclinical Studies ................................ ...................... 16 
1.4. Summary of Known Risks and Benefits to Human Subjects ................................ ...17 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical 
Study ……………………………………………………………………………………...17 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ................................ ......17 
2.1. Objectives ................................ ................................ ................................ ................. 17 
2.2. Endpoints ................................ ................................ ................................ .................. 17 
2.3. Hypotheses ................................ ................................ ................................ ............... 18 
3. TARGETED STUDY POPULATION ................................ ................................ ........... 18 
3.1. General Characteristics ................................ ................................ ............................ 18 
3.2. Inclusion Criteria ................................ ................................ ................................ ......18 
3.3. Exclusion Criteria ................................ ................................ ................................ .....19 
3.4. Enrollment Strategy ................................ ................................ ................................ ..19 
4. STUDY DESIGN AND RATIONALE ................................ ................................ .......... 20 
4.1. Description of Study Design ................................ ................................ .................... 20 
4.2. Study Design Rationale ................................ ................................ ............................ 20 
4.3. Enrollment Target and Study Duration ................................ ................................ ....20 
5. TEST ARTICLE ALLOCATION AND MASKING ................................ ..................... 21 
5.1. Test Article Allocation ................................ ................................ ............................. 21 
5.2. Masking ................................ ................................ ................................ .................... 21 
5.3. Procedures for Maintaining and Breaking the Masking ................................ ........... 22 
6. STUDY INTERVENTION ................................ ................................ ............................. 22 
CR-6478, v1.0 
Page 2 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.1. Identit y of Test Articles ................................ ................................ ............................ 22 
6.2. Ancillary Supplies/Products ................................ ................................ ..................... 23 
6.3. Administration of Test Articles ................................ ................................ ................ 24 
6.4. Packaging and Labeling ................................ ................................ ........................... 24 
6.5. Storage Conditions ................................ ................................ ................................ ...24 
6.6. Collection and Storage of Samples ................................ ................................ .......... 24 
6.7. Accountability of Test Articles ................................ ................................ ................ 25 
7. STUDY EVALUATIONS ................................ ................................ .............................. 25 
7.1. Time an d Event Schedule ................................ ................................ ......................... 25 
7.2. Detailed Study Procedures ................................ ................................ ....................... 27 
VISIT 1 ................................ ................................ ................................ ........................... 27 
VISIT 2 ................................ ................................ ................................ ........................... 33 
VISIT 3 ................................ ................................ ................................ ........................... 35 
VISIT 4 ................................ ................................ ................................ ........................... 36 
FINAL EVALUATION ................................ ................................ ................................ ..38 
7.3. Unscheduled Visits ................................ ................................ ................................ ...38 
7.4. Laboratory Procedures ................................ ................................ ............................. 40 
8. SUBJECTS COMPLETION/WITHDRAWAL ................................ .............................. 40 
8.1. Completion Criteria ................................ ................................ ................................ ..40 
8.2. Withdrawal/Discontinuation from the Study ................................ ........................... 40 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 41 
9.1. Systemic Medications ................................ ................................ .............................. 41 
10. DEVIATIONS FROM THE PROTOCOL ................................ ................................ ..42 
11. STUDY TERMINATION ................................ ................................ ........................... 43 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS .............. 44 
13. ADVERSE EVENTS ................................ ................................ ................................ ...45 
13.1.  Definitions and Classifications ................................ ................................ ............. 45 
13.2.  Assessing Adverse Events ................................ ................................ .................... 47 
13.2.1.  Causality Assessment ................................ ................................ .................... 48 
13.2.2. Severity Assessment ................................ ................................ ...................... 48 
13.3.  Documentation and Follow -Up of Adverse Events ................................ .............. 48 
13.4.  Reporting Adverse Events ................................ ................................ .................... 50 
13.4.1.  Reporting Adverse Events to Sponsor ................................ .......................... 50 
CR-6478, v1.0 
Page 3 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4.2.  Reporting Adverse Events to the Res ponsible IEC/IRB and Health Authorities
………………………………………………………………………………51 
13.5.  Event of Special Interest ................................ ................................ ....................... 51 
13.6.  Reporting of Pregnancy ................................ ................................ ........................ 51 
14. STATISTICAL METHODS ................................ ................................ ........................ 51 
14.1.  General Considerations ................................ ................................ ......................... 51 
14.2.  Sample Size Justification ................................ ................................ ...................... 52 
14.3.  Analysis Populations ................................ ................................ ............................ 52 
14.4.  Level of Statistical Significance ................................ ................................ ........... 52 
14.5.  Primary Analysis ................................ ................................ ................................ ..52 
14.6.  Secondary Analysis ................................ ................................ .............................. 52 
14.7.  Exploratory Analysis ................................ ................................ ............................ 52 
14.8.  Interim Analysis ................................ ................................ ................................ ...53 
14.9.  Procedure for Handling Missing Data and Drop -Outs ................................ ......... 53 
14.10.  Procedure for Reporting Deviations from Statistical Plan ................................ ...53 
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING ................................ 53 
15.1.  Electronic Case Report Form/Data Collection ................................ ..................... 53 
15.2.  Subject Record ................................ ................................ ................................ ......54 
15.3.  Trial Registration on ClinicalTrials.gov ................................ ............................... 54 
16. DATA MANAGEMENT ................................ ................................ ............................. 54 
16.1.  Access to Source Data/Document ................................ ................................ ........ 54 
16.2.  Confidentiality of Information ................................ ................................ .............. 54 
16.3.  Data Quality Assurance ................................ ................................ ........................ 55 
16.4.  Data Monitoring Committee (DMC) ................................ ................................ ....55 
17. CLINICAL MONITORING ................................ ................................ ........................ 55 
18. ETHICA L AND REGULATORY ASPECTS ................................ ............................ 56 
18.1.  Study -Specific Design Considerations ................................ ................................ .56 
18.2.  Investigator Responsibility ................................ ................................ ................... 56 
18.3.  Independent Ethics Committee or Institutional Review Board (IEC/IRB) .......... 56 
18.4.  Informed Consent ................................ ................................ ................................ .57 
18.5.  Privacy of Personal Data ................................ ................................ ...................... 58 
19. STUDY RECORD RETENTION ................................ ................................ ................ 59 
20. FINANCIAL CONSIDERATIONS ................................ ................................ ............ 60 
21. PUBLICATION ................................ ................................ ................................ ........... 60 
CR-6478, v1.0 
Page 4 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
22. REFERENCES ................................ ................................ ................................ ............ 60 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) .....61 
APPENDIX B: PATIENT INSTRUCTION GUIDE ................................ ............................. 72 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ................................ ......... 73 
APPENDIX D: ................................ ......79 
, LENS FITTING CHARACTERISTICS ................................ .............................. 80 
, SUBJECT REPORTED OCULAR SYMPTOMS ................................ ............... 86 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
................................ ................................ ................................ ................................ ................. 88 
 BIOMICROSCOPY SCALE ................................ ................................ ............... 94 
, DISTANCE AND NEAR VISUAL ACUITY EVALUATION ........................ 100 
 TORIC FIT EVALUATION ................................ ................................ .............. 105 
 ETDRS DISTA NCE VISUAL ACUITY MEASUREMENT PROCEDURE ..110 
 PATIENT REPORTED OUTCOMES ................................ .............................. 114 
 LENS INSERTION AND REMOVAL ................................ ............................. 116 
 VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING ................................ ................................ ................................ .............................. 119 
APPENDIX E:  GUIDELINES FOR COVID -19 RISK MITIGATION ............ 128 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE ........................ 140 
 
LIST OF TA BLES
Table 1: Test Articles ................................ ................................ ................................ .............. 23 
Table 2: Ancillary Supplies ................................ ................................ ................................ ....23 
Table 3: Time and Events ................................ ................................ ................................ ....... 25 
Table 4: Disallowed systemic medications ................................ ................................ ............. 41 
Table 5: Disallowed systemic antihistamines ................................ ................................ ......... 42 
Table 6: Examples of major a nd minor protocol deviations ................................ ................... 43 
 
LIST OF FIGURES
Figure 1: Study Flowchart ................................ ................................ ................................ ......14 
 
CR-6478, v1.0 
Page 5 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL TITLE, NUMBER, VERSION  AND DATE  
Title: Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week 
of Wear
Protocol Number: CR-6478
Version: 1.0
Date: 15 December 2021
SPONSOR NAME AND ADDRES S 
Johnson & Johnson Vision Care , Inc. (JJVC)
7500 Centurion Parkway 
Jacksonville, FL 32256
MEDICAL MONITOR  
Name: 
Title: 
Address: 
24 Hour Contact Telephone #
Email: 
The Medical Monitor must be notified by the clinical institution/si te by e -mail or telephone 
within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be contacted 
during business hours for adverse event questions. General study related questions should be 
directed towards your assigned clinical rese arch associate.
The Medical Monitoring Plan is maintained as a separate document and inc luded in the Trial 
Master File.
 
CR-6478, v1.0 
Page 6 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
AUTHORIZED SIGNATURES  
The signature sbelow constitutes the approval of this protocol and the attachments and provide 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statement s regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. federal regulations,4ISO 14155 :2020 ,1ICH 
guidelines,2and the Declaration of Helsinki.3
Author & Study 
Responsible Clinician
See Electronic Signature Report 
DATE
Clinical Operations 
Manager See Electronic Signature Report
DATE
Biostatistician See Electronic Signature Report
DATE
Data Management See Electronic Signature Report
DATE
Medical Safety 
Officer See Electronic Signature Report
DATE
Approver See Electronic Signature Report
DATE
 
CR-6478, v1.0 
Page 7 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SYNOPSIS  
Protocol Title Clinical Evaluation of Two Daily Disposable Toric Soft 
Contact Lenses Over One Week of Wear
Sponsor JJVC, 7500 Centurion Parkway, Jacksonville, FL  32256
Clinical Phase Descriptive study phase: Post-market
Design control phase: Post-market, phase 4
Trial Registration This study will be registered on ClinicalTrials.gov by the 
Sponsor.
Test Article(s) Approved Products: 
Test: PRECISION1®for Astigmatism Contact Lenses (P1fA)
Control: MyDay®Toric Soft Contact Lenses (MDT)
Wear and Replacement 
SchedulesWear Schedule: Daily wear
Replacement Schedule: Daily disposable
Objectives Primary Objective:
To evaluate the incidence of grade 3 or higher biomicroscopy findings
following a 7(±2) day wear period for PRECISION1®
for Astigmatism Contact Lenses (P1fA) relative to MyDay®
Toric Soft Contact Lenses (MDT) as control.
Exploratory Objectives:
To evaluate the subjective comfort, vision and handling, 
visual acuity, and rotational performance over a 7 (±2) day 
wear period for P1fA relative to MDT as control.
CR-6478, v1.0 
Page 9 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Study Endpoints Primary endpoint:
xIncidence of grade 3 or higher biomicroscopy findings 
using the FDA grading scale following a 7(±2) day
wear period
Observational endpoints (efficacy):
xSubjective comfort, vision and handling at fitting and 
following a 7(±2) day wear period using the CLUE 
questionnaire
xHigh-luminance, high-contrast (HLHC) v isual acuity
in logMAR measured using ETDRS charts at follow-
up
xLens orientation at 1 minute and 3 minutes following 
insertion at fitting
xMean and standard deviation of settled lens orientation
calculated from repeated measures of settled lens
orientation at fitting and follow-up visits 
Observational endpoints (safety):
xAdverse events
All endpoints will be summarized  using descriptive statistics 
only; no formal hypothesis testing is planned.
Study Design This is a bilateral, dispensing, randomized, controlled, double 
masked, 2×2 cross -over study. Each subject will be randomly 
assigned to one of two wear sequences (test followed by 
control or control followed by test). Each wear period will be 7(±2) days, with a 7(±2) day washout period between wear periods. 
There will be a total of 4 visits:
Visit 1: Screening, baseline evaluation and lens fit #1 Visit 2: Follow
-up evaluation for first lens
Visit 3: Continuance, lens fit #2
Visit 4: Follow -up evaluation for second lens
See the flow chart at the end of the synopsis table for a
schematic of the study visits a nd procedures (Figure 1).
Sample Size This study will have an e nrollment target of approximately 66 
subjects, with a target of at least 60 to complete (assuming a 
dropout rate of 10%).
Study Duration Total study duration including the enrollment period is 
anticipated to be approximately 8 weeks.
CR-6478, v1.0 
Page 10 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Anticipated Study 
PopulationSubjects will be habitual soft contact lens wearers with 
bilateral astigmatism who are between 18 and 39 years of age (inclusive).
Eligibility Criteria -
InclusionPotential subjects must satisfy of all the following criteria to 
be enrolled in the study.
Inclusion Criteria following Screening
The subject must:
1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the form. 
2. Appear able and willing to a dhere to the instructions set 
forth in this clinical protocol.
3. Be between 18 and 39 (inclusi ve) years of age at the time
of screening.
4.By self- report, habitually wear soft contact lenses in both 
eyes in a daily reusable or daily disposable wear modality 
(i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum 
of 2 days per week during the past month.
5. Possess a wearable pair of spectacles that provide 
correction for distance vision.
Inclusion Criteria at Baseline Evaluation
The subject must:
6.Have the spherical component of their vertex- corrected 
distance refraction must be between -0.875 to - 4.625 DS 
(inclusive) in each eye.
7. Have the magnitude of the cylindrical component of their 
vertex- corrected distance refraction between 0.625 DC 
and 1.625 DC in both eyes.
8. Have the cylinder axis of th eir distance refraction between 
165° and 15° (i.e., 180±15°, inclusive) or between 75° and 
105° (i.e., 90±15°, inclusive) in each eye.  
9. Have best corrected monocular distance visual acuity of 
20/30 or better in each eye.
CR-6478, v1.0 
Page 11 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria –
ExclusionPotential subjects who meet any of the following criteria will 
be excluded from participating in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating.
2.Be diabetic.
3.Be currently using any ocular  medications or have any 
ocular infection of any type.
4.By self- report, have any ocular or systemic disease, 
allergies, infection, or use of medication that might 
contraindicate or interfere with contact lens wear, or 
otherwise com promise study endpoints, including 
infectious disease (e.g., hepatitis, tuberculosis), 
contagious immunosuppressive disease (e.g., Human 
Immunodeficiency Virus [ HIV]), autoimmune disease 
(e.g. rheumatoid arthritis, Sjögren’s syndrome), or history 
of serious mental illness or seizures. See section 9.1 for 
additional details regarding excluded systemic 
medications. 
5.Have habitually worn rigid gas permeabl e (RGP) lenses, 
orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, 
SoftPerm) within the past 6 months.
6. Be currently wearing monovision or multifocal contact 
lenses.
7. Be currently wearing lenses in  an extended wear modality.
8.Have a history of strabismus or amblyopia.
9. Be an employee (e.g., Investigator, Coordinator, 
Technician) or immediate fami ly member of an employee 
(including partner, child, pa rent, grandparent, grandchild 
or sibling of the employee or their spouse) of the clinical 
site.
10.Have parti cipated in a contact lens or lens care product 
clinical trial within 7 days prior to study enrollment.
Exclusion Criteria at Baseline Evaluation
The subject must not:
11.Have clinically significant (g rade 3 or higher on the FDA 
grading scale) slit lamp findi ngs (e.g., corneal edema, 
neovascularization or stain ing, tarsal abnormalities or 
bulbar injection) or other corn eal or ocular disease or 
abnormalities that contraindica te contact lens wear or may 
otherwise compromise study endpoints (including 
entropion, ectropion, chalazia, recurrent styes, glaucoma, 
history of recurrent corneal erosions, aphakia, moderate or 
above corneal distortion, herpetic keratitis). 
CR-6478, v1.0 
Page 12 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
12. Have fluctuations in vision due to clinically significant dry 
eye or other ocular conditions. 
13.Have had or have planned (within the study period) any 
ocular or intraocular surgery (e.g., radial keratotomy, 
PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
Disallowed 
Medications/Interventions Subjects will not be eligible to enroll if they are taking any 
ocular medications, or any systemic medications that would 
normally contraindicate contact lens wear or may otherwise 
compromise study endpoints . See section 9.1 for details 
regarding disallowed systemic medications.
Measurements and 
ProceduresThe key procedures associated with the observational 
endpoints for this study will be:
-Grading of ocular physiology by slit lamp biomicroscopy 
using the FDA grading scale
- Completion of the CLUE que stionnaire at fitting and 
follow-up
- Measurement of HLHC VA using ETDRS charts at follow-
up
-Measurement of toric lens orientation using a slit lamp 
biomicroscope
Microbiology or Other 
Laboratory TestingNot applicable for this study.
Study Termination The occurrence of an Unanticip ated Adverse Device Effect 
(UADE) or Serious Adverse Event (SAE) for which a causal 
relationship to a test article cannot be ruled out, will result in 
stopping further dispensing investigational product. In the 
event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the Principal Investigator before any further subjects 
are enrolled.
Ancillary Supplies/ Study-
Specific MaterialsLens cases, fluorescein strips and preservative-free rewetting 
drops / artificial tears will be supplied for use as needed.  
Principal Investigator(s) 
and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.
CR-6478, v1.0 
Page 13 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Figure 1: Study Flowchar t
Visit 1: Screening
Statement of Informed Consent
Demographics
Medical History & Concomitant Medications
Habitual Contact Lens Information
Eligibility at Screening
Baseline Evaluation
Subject Reported Ocular Symptoms
Entrance visual acuity
Spherocylindrical refraction and distance visual acuity
Slit lamp biomicroscopy findings
Eligibility after Baseline
Baseline CLUE questionnaire (habitual lenses)
Lens Fitting (#1 through #3)
Lens assignment and insertion
Timed rotation assessments, lens settling
Toric and general fit assessment
Spherical over- refraction, modification if required
CLUE post-fit questionnaire
Additional samples of toric lens orientation
Lenses dispensed for 7 r2 days
Follow-up (#1 through #3)
CLUE follow-up questionnaire
HLHC visual acuity using ETDRS charts
Record lens orientation
Additional samples of toric lens orientationLens removal
Biomicroscopy
Schedule next visitContinuance
Review med history and medications
Subject reported ocular symptoms
Entrance VA and biomicroscopy
Confirm continuing eligibility
Final Evaluation
Spherocylindrical refraction
Completion status
Biomicroscopy (if discontinued early)After follow-up #1
After follow-up #2Washout Period
A washout period of 7r2 days duration 
will be observed between wear periods
CR-6478, v1.0 
Page 14 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
COMMONLY USED ABBREVIATIONS , ACRONYMS  AND DEFINITIONS OF 
TERMS  
Add Near addition; the additional power required for near vision correction 
ADE Adverse Device Effect
ADHD Attention Deficit Hyperactivity Disorder
AE Adverse Event/Adverse Experience
BSCVA Best Spectacle Corrected Visual Acuity
CFR Code of Federal R egulations
CLUE Contact Lens User Experience
COM Clinical Operations Manager
COVID -19 Coronavirus Disease 2019
CRA Clinical Research Associate
CRF Case Report Form
CRO Contract Research Organization
D Diopter
DMC Data Monitoring Committee
eCRF Electronic Case Report Form
EDC Electronic Data Capture
ESD Eyelid Stabilized Design
ETDRS Early Treatment Diabetic Retinopathy Study
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
HIV Human Immunodeficiency Virus
IB Investigator’s Brochure
ICH The International Council for Harmonization
IDE Investigational Device Exemption
IEC Independent Ethics Committee
IRB Institutional Re view Board
ISO International Organization for Standardization
ITT Intent -to-Treat
JJVC Johnson & Johnson Vision Care, Inc.
LASIK Laser -Assisted in Situ Keratomileusis
LogMAR Logarithm of Minimal Angle of Resolution
MDT MyDay®Toric Soft Contact Lenses
OD Right Eye
OS Left Eye
OU Both Eyes
P1fA PRECISION1®for Astigmatism Contact Lenses
PIG Patient Instruction Guide
PQC Product Quality Complaint
PRK Photorefractive Keratectomy
PRO Patient Reported Outcome
QA Quality Assurance
CR-6478, v1.0 
Page 15 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SAE Serious Adverse Event/Serious Adverse Experience
SAP Statistical Analysis Plan
SAS Statistical Analysis System
SD Standard Deviation
UADE Unanticipated Adverse Device Effect
USADE Unanticipated Serious Adverse Device Effect
VA Visual Acuity
1.INTRODUCTION AND BACKGROUND  
PRECISION1®(verofilcon A) for Astigmatism Contact Lenses (P1fA) and MyDay®
(stenfilcon A) Toric Soft Contact Lenses (MDT) are daily disposable lenses indicated for the 
correction of astigmatism and associate d ametropia in persons with non -diseased eyes. The 
purpose of this study is to evaluate the ocular physiological response following wear of P1fA 
relative to MDT as control. 
1.1. Name and Descriptions of Investigational Products  
The test lens in this study wil l be P1fA. P1fA contact lenses are made from a lens material that 
is 51% water and 49% verofilcon A, a silic one containing hydrogel. The color additive 
Reactive Blue 247 is added to the lens material to create a light blue edge -to-edge color to 
make it eas ier to see when handling. In addition, lenses contain a benzotriazole UV -absorbing 
monomer to block UV radiation. The transmittance characteristics are less than 1% in the UVB 
range of 280 nm to 315 nm and less than 10% in the UVA range of 316 to 380 nm fo r the entire 
power range.
The control lens in this study will be MDT, which is made from stenfilcon A . The stenfilcon 
Amaterial is primarily a random copolymer of polydimethylsiloxane methacrylate and 
vinylmethyl acetamide. The UV blocker used is a benzotriazolyl methacrylate. The lenses have 
a blue tint which is added to make the lens more visible for handling. The lenses also contain 
a UV absorbing monomer which is used to block UV radiation .
Further details about the test articles are found in s ection 6.1of this protocol and in the P1fA 
and MDT package insert s(Appendix C).
1.2. Intended Use of Investigational Products  
The intended use of the investigati onal product sisthe correction of astigmatism and associated 
myopi c refractive error .Study lenses will be worn bilaterally  in a daily wear, daily disposable 
modality for at least 8 hours per day. Each wear period will be  7±2 (i.e., 5 to 9) days in duration, 
and subjects will be instructed to wear lenses for at least 5 days per week during each wear 
period. Two wear periods will be completed, with a washout period of 7±2days between the 
wear periods.
1.3. Summary of Findings from Nonclinical Studies  
Not Applicable –marketed product only.
CR-6478, v1.0 
Page 16 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
1.4. Summary of Known Risks and Benefits to Human Subjects  
Theanticipated clinical benefit of the investigationa l lenses will be the correction of refractive 
error. The risks associated with use of the investigati onal lenses are considered to be equivalent 
to those associated with other marketed soft contact lenses worn in the same modality (i.e., 
daily disposable).  
Comprehensive risk and benefit information regarding the P1fA and MDT lensesare included 
intheP1fA and MDT package insert s(Appendix C).
1.5. Relevant Literature References and Prior Clinical Data Releva nt to Proposed 
Clinical Study  
Both P1fA and MDT are approved in the US for  the correction of astigmatism and associated 
ametropia in persons with non -diseased eyes. 
For further details regarding literature references and prior data relevant to the selenses , refer 
to the P1fA and MDT package insert s(Appendix C).
2.STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES  
2.1. Objectives  
Primary Objective:
To evaluate the incidence of grade 3 or higher biomicroscopy findings following a 7(±2) day 
wear period forPRECISION1®for Astigmatism Contact Lenses (P1fA) relative to MyDay®
Toric Soft Contact Lenses (MDT) as control .
Exploratory Objectives:
To evaluate the subjective comfort, vision and handl ing, visual acuity, and rotational 
performance over a 7 (±2) day wear period for P1fA relative to MDT as control.
2.2. Endpoints  
Primary endpoint:
xIncidence of grade 3 or higher biomicroscopy findings using the FDA grading scale 
following a 7(±2) day wear period 
Observational endpoints (efficacy) :
xSubjective comfort, vision and handling at fitting and following a 7(±2) day wear 
period using the CLU E questionnaire
xHigh -luminance, high -contrast (HLHC) visual acuity in logMAR measured using 
ETDRS charts at follow -up
xLens orientation at 1 minute and 3 minutes following insertion at fitting
xMean and standard deviation of se ttled lens orientation calculat ed from repeated 
measures of settled lens orientation at fitting and follow -up visits 
CR-6478, v1.0 
Page 17 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Observational endpoints (safety):
xAdverse events
All endpoints will be summarized using descriptive statistics only; no confirmatory hypothesis
testing is planned.
2.3. Hypotheses  
Not applicable; no confirmatory hypothes is testing for the primary endpoint is planned with 
respect to data collected in this study .Therefore, any hypothesis testing will be exploratory in 
nature.
3.TARGETED STUDY POPULATION  
3.1. General Characteristic s  
Thetarget population for this study will be healthy adult soft contact lens wearers between 18 
and 39 years of age with binocular myopic astigmatism.  
3.2. Inclusion Criteria  
Potential subjects must satisfy all of the following criteria to be enrolled in t he study:
Inclusion Criteria atScreening
The subject must:
1.Read, understand, and sign the STATEM ENT OF INFORMED CONSENT and 
receive a fully executed copy of the form .
2.Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3.Be between 18 and 39 (inclusive) years of age at the time of screening.
4.By self -report, habitually wear soft contact lense s in both eyes in a daily reusable or 
daily disposable wear modality (i.e. not extended wear modality). Habitual wear is 
defined as a minimum of 6hours of wear per day, for a minimum of 2days per week 
during the past month.
5.Possess a wearable pair of spectacles that provide correction for distance vision.
Inclusion Criteria atBaseline Evaluation
The subject must:
6.Have t he spherical component of the irvertex -corrected distance refraction must be 
between -0.875 to -4.625 DS (inclusive) in each eye.
7.Have t he magnitude of the cylindrical co mponent of their vertex -corrected distance 
refraction between 0. 625DC and 1.625 DC in both eyes .
8.Have the cylinder axis of their dist ance refraction between 165° and 15° ( i.e.,180±15°, 
inclusive) or between 75 °and 105 ° (i.e. ,90±15°, inclusive) in each eye.  
9.Have best corrected monocular distance visual acuity of 20/30 or better in each eye.
CR-6478, v1.0 
Page 18 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
3.3. Exclusion Criteria  
Potential subjects who meet any of the following criteria wil l be excluded from participating 
in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating.
2.Be diabetic.
3.Be currently using any ocular medications or have any ocular infection of any type.
4.By self -repor t, have any ocular or systemic di sease, allergies, infection, or use of 
medication that might contraindicate or interf ere with contact lens wear, or otherwise 
compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), 
contagi ous immunosuppressive disease (e.g., Human Immunodeficiency Virus [ HIV]), 
autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), or history of 
serious mental illness or seizures. See section 9.1for additional details regarding 
excluded systemic medications. 
5.Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or 
hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
6.Be currently wearing monovision or multifocal contact lenses.
7.Be currently wearing lenses in an extended wear modality.
8.Have a history of strabismus or amblyopia.
9.Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family 
member of an employee (including partner, ch ild, parent, grandparent, grandchild or 
sibling of the employee or their spouse) of the clinical site.
10.Have participated in a contact lens or lens care product clinical trial withi n 7 days prior 
to study enrollment.
Exclusion Criteria atBaseline Evaluation
The subject must not:
11.Have clinically significant ( grade 3 or higher on the FDA grading scale) slit lamp 
findings (e.g., corneal edema, neova scularization or staining, tarsal ab normalities or 
bulbar injection) or other corne al or ocular disease or abnorm alities that contraindicate 
contact lens wear or may otherwise compromise study endpoints (including entropion, 
ectropion, chalazia, recurrent stye s, glaucoma, history of recurren t corneal erosions, 
aphakia, moderate or above corneal distortion, herpetic keratitis). 
12.Have fluctuations in vision due to clinica lly significant dry eye or other ocular 
conditions. 
13.Have had or have planned (within the study period) any ocular or intraoc ular surgery 
(e.g., radial keratotomy, PRK, LASIK, iridot omy, retinal laser photocoagulation, etc.).
3.4. Enrollment Strategy  
Study subjects will be recruited from the Inst itution/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (I EC) or Institutional Review Board (IRB) approved 
materials. 
CR-6478, v1.0 
Page 19 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
4.STUDY DESIGN AND RATIONALE  
4.1. Description of Study Design  
This will be a 4-visit, randomized, controlled, double -masked, bilateral wear, dispensing, 2 ×2
crossover study. Each subject will be randomized into one of twounique sequences to wear 
twodifferent study lenses one at a time over twowear periods (test followed by control or 
control followed by test).During each wear period the lenses will be worn bilaterally for 1
week (7r2 days) in a daily disposable modality .Study lenses will be worn for a minimum of 
8 hours per day and at least 5 da ys per week during the wear peri od. Subjective comfort, vision 
and handling will be assessed using the CLUE questionnaire at both fitting and follow -up visits 
for each wear period. HLHC VA will be assessed at the follow -up evaluation using ETDRS 
charts. Ocular health will be assessed by slit lamp biomicroscopy and graded using the FDA 
grading scale at fitting and follow -up visits. There will be a washout period of 7r2 days 
duration between wear periods. Subjects will not have access to the study lenses following 
completion of the protocol.
4.2. Study Design Rationale  
A 2×2 crossover study design was chosen to allow each subject toact as t heir own active 
control. Awashout period will be included to mitigate any carryover effects. 
The prescribed wear schedule (7 r2 days, minimum of 8 hours per day, minimum of 5 days per 
week) was chosen as this is representative of a typical wear schedule for contact lens wearers.
Slit lamp biomicroscopy was selected as the method for assessing ocular health, on the basis 
that it is the most commonly used instrument for comprehensive examination of the anterior
eye. The FDA slit lamp findings classification scale was selected for grading ocular health on
the basis that it is widely used and is part of the FDA regulatory guidance for contact lenses
(FDA 510(k) guidance). 
The investigational lenses will be fitted by optometrists who are experienced at fitting toric 
soft contact lenses and will be evaluated by habitual contact lens wearers in their standard 
wearing environment.
4.3. Enrollment Target and Study Duration  
This study will have an enrollment target of approximately 66 subjects, with a target of at least 
60to complete. The study will be conducted at up to 5 clinical sites , where the enrollment 
target for each site will be approximately 14 subjects. A subject  will be considered enrolled 
upon signing of the informed consent form.  
There will be 4 visits in total per subject . The total study duration including the enrollment 
period is expected to be  approximately 8 weeks. Subjects who are discontinued prior to the 
final evaluation may b e replaced at the discretion of the study sponsor .The investigation will 
end at the time that the study data is hard locked.
CR-6478, v1.0 
Page 20 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
5.TEST ARTICLE ALLOCATION AND MASKING  
5.1. Test Article Allocation  
This study will be a randomized, double -masked, 2 ×2 crossover design. Subjects will be 
randomized into one of 2 unique sequence groups in a 1:1 allocation ratio to wear two different 
study lens designs (test and control designs) one at a time bilaterally over 2 wear periods. 
Use of the test articles wil l be randomized using a randomization scheme supplied by the study 
biostatistician.  The randomized assignment of subj ects will be performed at the first visit prior 
to the first fitting. C linical sites will follow the randomization scheme provided and wil l not 
pre-select or assign subjects. The following must have occurred prior to randomization:
xInformed consent must have been obtained
xThe subject must have met all inclusion and exclusion criteria
xThe subject history and baseline information must have bee n collected
Randomly permuted block randomization will be us ed to avoid bias in the assignment of 
subjects to treatment and to enhance the vali dity of statistical comparisons across treatment 
groups.
When dispensing test articles, the following steps sho uld be followed to maintain 
randomization codes:
1.Investigator or designee (documented on the Delegation Log) will consult the 
randomization scheme (lens fitting schedule) to obtain the test article assignment for 
that subject prior to dispensing .
2.Investiga tor or designee will record the subject’ s number on the appropriate line of the 
randomization scheme (lens fitting schedule).
3.Investigator or designee will pull the appropriate test articles from the study supply. 
All test articles that are opened, whethe r dispensed (placed/fit on eye or dispensed 
outside the clinical site) or not, must be recorded on the Test Article Accountability 
Log in the “Dispensed” section.
5.2. Masking  
To reduce the possibility of bias, this will be a double -masked trial . Subjects will notbe aware 
of the identity of the assigned lenses. The identity of the study lenses will be masked by having 
the blister packs labeled with the study number, lot number, sphere power, cylinder power, 
axis, expiration date and randomization c ode. While clinical trial personnel (including
investigators, site technicians, d ata management, the study b iostatistician and clinical 
operations personnel )will be aware of the brand and type of lenses included in the study, e very 
attempt will be made to ensure they are not made aware of the corresponding randomization 
codes for the test and control lenses .Only the unmasked Biosta tistician generating the 
randomization scheme (lens fitting schedule) will have access to the decode information that
allows matching of the randomization codes to the investigational articles. The medical 
monitor will also have access to the d ecode information in case breaking the mask is necessary 
for the urgent medical treatment of a subject.
CR-6478, v1.0 
Page 21 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
5.3. Procedures for Maintaining and Breaking the Masking  
Under normal circumstances, the mask should not be broken until all subjects have completed 
the study and the datab ase is finalized. Otherw ise, the mask should be broken only if specific 
emergency treatment/course of action would be dictated by kno wing the treatment status of the 
subject. In such cases, the Investigator may, in  an emergency, contact the medical monitor. In 
the event the mask is broken, the Sponsor must be informed as soon as possible. The date, 
time, and reason for the unmasking must be docum ented in the subject record. The Investigator 
is also advised not to reveal the study trea tment assignment to the clinical site or Sponso r
personnel. 
Subjects who have had their treatment assignment unmasked are expected to return for all 
remaining scheduled evaluations. Subjects who are discontinued may be replaced at the 
discretion of the study sponsor .
6.STUDY INTERVENTION  
6.1. Identity of Te st Articles  
The following contact lenses will be used in this study:
CR-6478, v1.0 
Page 22 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
NOTE : If the only reason for the unscheduled vi sit is that the subject requires additional 
test articles, only the dispensing information needs to be recorded.
7.4. Laboratory Procedures  
Not applicable.
8.SUBJECTS COMPLETION/WITHDRAWAL  
8.1. Completion Criteria  
Subjects are considered to have completed the study if they: 
xprovided informed consent .
xthey are eligible .
xhave not withdrawn/discontinued from the study for any reason described in section 
8.2.
xcompleted all visits through the final visit (visit 4).If all visits were completed but an 
additional visit is considered necessary for subject care, follow the requirements for 
unscheduled vis itsin section 7.3.
8.2. Withdrawal/Discontinuation from the Study  
A subject will be withdrawn from the study for any of the following reasons:
xSubject withdrawal of consent .
xSubject not compliant to protocol .
xSubject lost to follow -up.
xSubject no longer meets eligibility cri teria (e.g. the subject becomes pregnant) .
xSubject develops significant or serious adverse events necessitating discontinuation of 
study lens wear .
xSubjects who have experienced a Corneal Infiltrative Event (CIE) .
xInvestigator’s clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment) .
xSubject misse sanystudy visits .
xSubject not compliant with study lens wear schedule .
xSubject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit .
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled) .
xComplete the Final Evaluation, indicating the reason that the subject was discontinued 
from the study .
xRecord the spherocylindrical refraction with best corrected distance visual acuity .
xCollect used test article(s) (worn or brought to  the visit) from the subject and discard 
them, unless otherwise stated in section 7.2.
xCollect all unused test article(s) from the subject .
xMake arrangements for subject care, if needed, due to their study participation
CR-6478, v1.0 
Page 40 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study  if an unreasonable risk is determined. The 
study can be terminated by the Princip al Investigator at the individual clinical site due to 
specific clinical observations, if in their opinion, after a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicab le) will evaluate all adverse events. If it is 
determined that an adverse event presents an unre asonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible.
Should the study be terminated (either prematurely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements.
12.PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS  
A Product Quality Complaint (PQC) refers to any written , electronic, or oral communication 
that alleges deficiencies relate d to the identity, quality, dura bility, reliability, safety, 
effectiveness or performance of test articles after th ey have been released for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints:
xSubject s atisfaction inquiries reported via “Subj ective Questionnaires” and “Patient 
Reported Outcomes (PRO) .”
xClinical test articles that are stored improperly or damaged after receipt at the 
investigational site .
xLens replacements that occur due to drops/fall -outs.
xDamage deemed by clinicians or clinical staff to be caused by handling by the user, 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where 
there is no deficiency alleged by the subject .
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be 
recorded in the EDC system, which will tr igger an automatic email notification to the 
appropriate COM/CRA and Clin ical QA representative. In cases where the EDC syste m in use 
is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
Upon receipt of the EDC notification, the COM/CRA will contact the study site to collect 
additional information which will include: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor 
Awareness) .
xWho received the complaint .
xStudy number .
xClinical site information (contact name, site ID, telephone number) .
xLot number(s) .
CR-6478, v1.0 
Page 44 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xUnique Subject Identifier(s) .
xIndication of who first observed complaint (site personnel or subject) .
xOD/OS indication, along with whether the lens was inserted .
xAny related AE number if applicable .
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.) .
xEye Care Provider objective (sli t lamp) findings if applicable .
xConfirmation of product availability for return  (and tracking information, if available), 
or ratio nale if product is not available for return (Refer to Form Control No. 
for test article return instructions) .
Once a complaint is received, it will be asse ssed by the COM, CRA, or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow section 13of this 
protocol. I f the AE/SAE was potentially the result of a product quality related deficiency, these 
procedures also applies and will be executed in parallel.  
In some cases, a PQC form may be generated in EDC by the site in error. In this event, the 
PQC forms will be marked “Intentionally Left Blank” or “ILB”.  Justification for ILB must be 
documented.
13.ADVERSE EVENTS  
13.1. Definitions and Classifications  
Adverse Event (AE) –An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to  the investigational medical device. ”
Note :This definition includes events related to  the investigational medical device or the 
comparator , and to the procedures involved .For users or other persons, this definition is 
restricted to events related to investigational medical devices .1
An AE includes any condition (including a pre -existing condition) that:
1.Was not present prior to the study, but app eared or reappeared following initiation of 
the study .
2.Was present prior to the study but worsened  during the study. This would include any 
condition resulting from concomitant illnesse s, reactions to concomitant medications, 
or progression of disease states .
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event.
Serious Adverse Event (SAE) –An SAE is any adverse event thatled to any of the following :
xDeath
xSerious deterioration in the health of the subj ect that resulted in any of the following:
xLife-threatening illness or injury
CR-6478, v1.0 
Page 45 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xPermanent or persistent impairment of a body structure or a body function
xHospitalization or prolongation of patient hospitalization
xMedical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.
xChronic disease
xFoetal distress, foetal death or a congenita l physical or mental impairment of birth 
defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (M K)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best sp ectacle corrected visual acuity e quivalent to 2 acuity lines 
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epithelial Defect
xLimbal cell Damage leading to Conjunctivalization
Significant Adverse Events –are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the co ntact lens wear
Diagnoses and conditions that are considered Oc ular Significant Adverse Events include, but 
not limited to the following:
xContact Lens Induced Peripheral Ulcer (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epithelial Arcuate Lesion s (SEALs)
xAny Temporary Loss of > 2 Lines of BSCVA
xOther grade 3 or higher corneal findings, such as abrasions or edema
xNon-contact lens related corneal events -e.g. Epidemic Keratoconjunctivitis (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which nec essitates temporary lens discontinuation > 2 weeks
Non-Significant Adverse Events –are defined as those events that are usually asymptomatic 
and usually do not warrant discontinuation of con tact lens wear but may cause a reduction in 
wear time.  However, the Investigator may choose to prescri be treatment as a precautionary 
measure .
CR-6478, v1.0 
Page 46 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Diagnoses and conditions that are considered Ocular Non -Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact Lens Papillary Conjunctivitis (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact Dermatitis
xLocalized Allergic Reactions
xAny corneal event not explicitly defined as serious or si gnificant adverse event, which 
necessitates temporary lens discontinuation < 2 weeks
Adverse Device Effect (ADE) –An ADE is an “adverse event related to the use of an 
investigational medical device. ”
NOTE 1:This definition includes  adverse events result ing from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or 
any malfunction of the investigational medical device.
NOTE 2:This definition includes any event resulting from use error or from intentiona l
misuse of the investigational medical device.1
Unanticipated Adverse Device Effect (UADE) –A UADE is a ny serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, the test 
article, if that effect, problem, or death was not  previously identified in nature, severity, or 
degree of incidence in the investigationa l plan, Investigator’s Brochure or proto col, or any 
other unanticipated serious problem  associated with the test artic le that relates to the rights, 
safety and welfare of subjects.
13.2. Assessing Adverse Events  
In conjunction with the medical monitor, the In vestigator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization will include:
xSeriousness/Classifications (see definition in section 13.1).
xCausality or Relatedness –i.e. the relationship between the test article, study treatment 
or study procedures and the adverse event (not related ,unlikely related ,possibly
related ,orrelated -see definition in section 13.2.1 ).
xAdverse Event Severity –Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild ,moderate ,orsevere -see definition in 
section 13.2.2 ).
xOutcome –not recovered or not resolved ,recovering or resolving ,recovered or 
resolved with sequelae ,recovered or resolved ,death related to adverse event , or
unknown .
xActions Taken –none ,temporarily discontinued ,permanently discontinued , orother .
CR-6478, v1.0 
Page 47 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.2.1. Causality Assessment  
Causality Assessment –A determination of the relationship be tween an adverse event and the 
test article. The test article relationship f or each adverse event should be determined by the 
investigator using these explanations:
xNot Related -An adverse event that is not related to the use of the test article, study 
treatment or study procedures .
xUnlikely Related –An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomi tant disease(s), or the relationship of time 
suggests that a causal relationship is not likely .
xPossibly Related –An adverse event that might be  due to the use of the test article, or 
to the study treatment or study procedures. An  alternative explanation, e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is 
reasonable. Therefore, the causal relationship cannot be excluded .
xRelated –An adverse event that is listed as a po ssible adverse effect (device) or adverse 
reaction (drug) and cannot be reasonably exp lained by an alternative explanation, e.g. 
concomitant treatment of c oncomitant disease(s). The relationship in time is very 
suggestive, e.g. it is confirmed by de -challenge and re -challenge .
13.2.2. Severity Assessment  
Severity Assessment –A qualitative assessment of the degree of intensity of an adverse event 
as determined by the Investigator or report ed to him/her by the subject. The a ssessment of 
severity is made irrespective of test article, st udy treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to the following scale:
xMild –Event is noticeable to the subject but is easily tolera ted and does not interfere 
with the subject’s daily activities .
xModerate –Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s daily activities .
xSevere –Event is intolerable, necessitates additional therapy or alteration of therapy 
and interferes with the subject’s daily activities .
13.3. Documentation and Follow -Up of Adverse Events  
The recording and documenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study t reatment or study procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical  events reported after the subject’s 
exit from the study will be recorded as adve rse events at the discretion of the Investigator.
Upon finding an adverse event, the Principal Investigator will document the conditio n in the 
subject record and in the eCRFs andcomplete the Adverse Event eCRF.  
Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic  reactions not meeting the criteria for “se rious
adverse events” shall be capture d on the appropriate case report form or electronic data system. 
CR-6478, v1.0 
Page 48 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
All adverse events occurring while the subject is enrolled in the study  must be documented 
appropriately regardless of relationship.  
It is the Investi gator’s responsibility to maintain documen tation of each reported adverse event. 
All adverse events will be followed in accordan ce with applicable licensing requirements. Such 
documentation will include the following:
xAdverse event (diagnosis not symptom) .
xDrawings or photographs (where appropriate) that detail the finding (e.g., size, 
location, and depth, etc.) .
xDate the clinical site was notified .
xDate and time of onset .
xDate and time of resolution .
xAdverse event classification, severity, and relationship to test articles, as applicable .
xTreatment regimen instituted (where appropriate) , including concomitant medications 
prescribed, in accordance with applicable licensing requirements .
xAny referral to another health care provider if needed .
xOutcome, ocular damage (if any) .
xLikely etiology .
xBest corrected visual acuity at the disc overy of the event and upon conclusion of the 
event , if the AE is related to the visual system .
Upon discovery of an AE that is deemed ‘possibly related ’or ‘related ’to the test article or 
study procedures (whether related to the visual system or not), a nAE review form ( )
must be completed .Additional dated and initialed entries should be made atfollow -up 
evaluations .Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he /she will complete the Corneal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corne al lesion will be collected to determin e if the 
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at eac h level of intensity to be performed. Adverse events characterized as 
intermittent require documentation of the onset and duration of each episode. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.
Subjects wh o present with an adverse event shall be followed by the Investigator, within 
licensure, until all signs and symptoms have returned to pre -treatment status, stabilized, or 
been satisfactorily resolved. If further treatment beyond licensure is required, the patient will 
be referred to the appropriate health care provi der. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in the study. If 
a subject is discontinued from the study, it will be the responsibility of the Investigator to 
record the reason for discontinuation. The Investig ator will also document the adverse event 
appropriately and complete the Adverse Even t eCRF. Any subjects with ongoing adverse 
events related to the test articl e, study treatment or study proce dures, as of the final study visit 
CR-6478, v1.0 
Page 49 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
date, should be followed to resolution of the adverse event or until referral to an appropriate 
health care provider, as recommended by the Investigator. Non -ocular adverse events that are
not related to the test article, study treatmen t, or study procedures may be recorded as 
“ongoing” without further follow -up.
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e -mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from  discovery for any serious /significant 
adverse events, and 2 days from discovery for any non -significant adverse event. In addition, 
a written report will be submitted by th e Principal Investigator to the IEC/IR B according to 
their requirements ( section 13.4.2 ). The report will comment whether the adverse event was 
considered to be related to the test arti cle, study treatment or study procedures.
13.4.1. Reporting Adverse Events to Sponsor  
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e -mailor telephone, but no later than 24 hours 
following discovery of the event. The Invest igator is obligated to pursue and obtain 
information requested by the Sponsor in addition to that information reported on the eCRF. All 
subjects experiencing a serious /significant adverse event must be followed up and all outcomes 
must be reported.
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the s ubject received. The Sponsor and study monit or should 
be notified prior to unmasking the test articles.
In the event of a serious/significant adverse event, the Investigator must:
xNotify the Sponsor immediately .
xObtain and maintain in the subject’s records all pertinent medical information and 
medi cal judgment for colleagues who assi sted in the treatment and follow -up of the 
subject .
xProvide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article .
xNotify the IEC/IRB as required by the IEC/IRB reporting procedure according to 
national regulations .
Unanticipated (Serious) Adverse Device Effect (UADE)
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit a report o f the UADE to the Sponsor and IEC/I RB as soon as possible, but no later 
than 24 hours after the Investigator first learns of the effect. This report is in addition to the 
immediate notification mentioned above.
The Sponsor must conduct an evaluation of th e UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within 10 working days after 
the Sponsor first receives notification of the effect.
CR-6478, v1.0 
Page 50 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Non-Serious Adverse Events
All non -serious adverse events, includin g non -serious adverse device effects, will be reported 
to the sponsor by the Investigator no later than 2 days from discovery.
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth 
by their Approving IEC/IRB. Each clinical site will refer to and follow any guidelines set forth 
by their local governi ng Health Authorities.
The Sponsor will report applicable Adverse Events  to the local health authorities according to 
the written guidelines, including reporting timelines. 
13.5. Event of Special Interest  
None.
13.6. Reporting of Pregnancy  
Subjects reporting pregnan cy (by self -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinu ed from contact lens or solution related st udies for safety concerns, but due to 
general concerns relating to pregna ncy and contact lens use. Spec ifically, pregnant women are 
discontinued due to fluctuations in refrac tive error and/or visual acuity that oc cur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.
14.STATISTICAL METHODS  
14.1. General Considerations  
Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A 
general de scription of the statistical methods to be impleme nted in this clinical trial is outlined 
below.
All data summaries and statistical analyses will be performed using the SAS software Version 
9.4 or higher (SAS Institute, Cary, NC).  Throughout the analysi s of data, the results for each 
subject/eye will be used when available for summarization and statistical analysis.
Summary tables (descriptive statistics and/or freque ncy tables) will be provided for all baseline 
variables, efficacy variables and safety variables as appropriate. Continuous variables will be 
summarized with descriptive statistics (n, mea n, standard deviation (SD), median, minimum 
and maximum). Frequency count an d percentage of subjects or eyes within each category will 
be provided for cat egorical data.
CR-6478, v1.0 
Page 51 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.2. Sample Size Justification  
Approximately 66 subjects will be enrolled in this study to attain a minimum of 60 completed 
subjects.  All endpoints will be summar ized using descriptive statistics only; noconfirmatory 
hypotheses will be tested .  This is a descriptive study to eval uate the clinical performance of 
the P1fA and MDT lenses. Sample size is not based on the empirical power analysis. The data 
collected for this study may be used for designing future study if applicable.
14.3. Analysis Populati ons 
Safety Population:
All subjects who are administered any test article excluding subjects who drop out prior to 
administering any test article. At lea st one observation should be recorded.
Per-Protocol Population: 
All subjects who successfully complet e all visits and do not subs tantially deviate from the 
protocol as determined by the trial cohort revi ew committee prior to database hard lock. 
Justification for the exclusion of subjec ts with protocol deviations from the Per-Protocol 
Population set will b e documented in a memo to file.
Intent -to-Treat (ITT) Population:
All randomized subjects regardless of actual tr eatment and subsequent withdrawal from the 
study or deviation from the protocol. At least one observation should be recorded.
14.4. Level of Statist ical Significance  
Noconfirmatory hypothesis testing isplanned forthis study; hence, the level of statistical 
significance is not applicable .Ifexploratory statistical analysis is conducted after reviewing 
the descriptive summary ofanendpoint , a type I error rate will be specified forthe analysis .
Since all analyses for this study will be expl oratory in nature, any positive results given by  
significance p -value swill be for generating hypotheses for future studies and decisions are
required to make with caution s.
14.5. Primary Analysis  
Descriptive summary tables byLens Type (P1fA vs. MDT) forthe following safety and 
efficacy endpoints will be provided.
xIncidence of grade 3 or higher biomicroscopy findings using the FDA grading scale 
following a 7(±2) day wear period 
14.6. Secondary Analysis  
Not applicable.  
14.7. Exploratory Analys is 
Descriptive summary tables by Lens Type (P1fA vs. MDT) for the following explorat ory
endpoints will be provided
xSubjective comfort, vision and handling at fitting and following a 7(±2) day wear 
period using the CLUE questionnaire
CR-6478, v1.0 
Page 52 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xHigh luminance, high contrast (HLHC) logMAR visual acuity measured using ETDRS 
acuity charts at 1-Week follow-up
xLens orientation at 1 minute and 3 minutes following insertion at fitting
xMean and standard deviation of settled len s orientation, as calculated from repeated 
measures of signed lens orientation at fitting and follow -up visits.
Other e xploratory analyses will be determined after revi ewing the descriptive summary at the 
discretion of the study responsible clinician and project team. They may be performed on study 
endpoints between lens type (P1fA vs. MDT) or onendpoints collected in previous JJVC -
sponsored studies to generate hypotheses for future confirmatory studies.
14.8. Interim Analysis  
Not applicable. 
14.9. Procedure for Handling Missing Data and Drop -Outs  
Missing or spurious values will not be imputed. The count of missing values will be included 
in the summary tables and listings. 
14.10. Procedure for Reporting Deviations from Statistical Plan  
The analysis will be conducted according to th at specified in above sections. There are no 
known reasons for which it is planned to deviate from thes e analysis methods. If for any reason 
a change is made, the change will be documented in the study report along with a justification 
for the change.
15.DATA HANDLING AND RECORD KEEPING/ARCHIVING  
15.1. Electronic Case Report Form/Data Collection  
The data for this st udy will be captured on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data originator will enter study data into the eCRFs 
using the EDC system . Data collected on equipment that is not captured in EDC will be 
formatted to the specification of the JJVC database  manager and sent to JJVC for analysis. 
No e xternal datasources will be included in this study .
The clinical data will be recorded on dedicated eCRFs specifically designed to match the study 
procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by the 
Investigator. The sponsor or sponsor’s representative s will be authorized to gain access to the 
subject recordation for the purposes of monitoring and auditing the study. 
Edit checks, electronic queries, and audit trails ar e built into the system to ensure accurate and 
complete data collection. Data will be tr ansmitted from the clinical site to a se cure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
CR-6478, v1.0 
Page 53 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of 
the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant with ISO14155:20 20.1
15.2. Subject Record  
At a minimum, subject record should be available for the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
xresults of safety and efficacy parameters as required by the protocol
xa record of all adverse events
xfollow -up of adverse events
xmedical history and concomitant medicatio n
xtest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an externa l record. The author of an entry in the subj ect 
record must be identifiable. The first point of entry is considered to be the source record.
Adverse event notes must be reviewed and initialed by the Investigator.
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTri als.gov by the Sponsor.
16.DATA MANAGEMENT  
16.1. Access to Source Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents. Should the 
clinical site be contacted for an audit by an  IEC/IRB or regulatory authority, JJVC must be 
contacted and notified in writing within 24 hours.
16.2. Confidentiality of Information  
Information concerning the investigational product and patent application processes, scientific 
data or other pertinent information is confide ntial and remains the property of JJVC. The 
CR-6478, v1.0 
Page 54 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Investigator may use this information for the purposes of the study on ly. It is understood by 
the Investigator that JJVC will use information deve loped in this clinical study in connection 
with the development of the investigational product  and therefore may disclose it as required 
to other clinical investigators and to regu latory agencies. In order to allow the use of the 
information derived from this clinical study, the Investigator understands that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor.
16.3. Data Qualit y Assurance  
Steps will be taken to ensure the accuracy a nd reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and review of protocol procedures with 
the Principal Investigator. The Principal Investigator, i n turn, must ensure that all Sub -
Investigators and clinical site personnel ar e familiar with the protocol and all study -specific 
procedures and have appropriate knowledge of the study article.
Training on case report form completion will be provided to cl inical site personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepanci es will be resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pertaining to the con duct 
of clinical trials. The clinical sites will provide direct access to study -related source 
data/documents and reports for the purpose of monitoring and auditing by JJVC and for 
inspection by local and regulatory authorities.
16.4. Data Monitoring Committee  (DMC)  
Not applicable for this study. 
17.CLINICAL MONITORING  
The study monitors will maintain close contact with the Principal Investigator and the 
Investigator’s designated clinical site personnel. The monitor’s responsibilities will include:
xEnsuring that th e investigation is being conducted  according to the protocol, any 
subsequent versions , and regulatory requirements are maintained .
xEnsuring the rights and wellbeing of subjects are protected .
xEnsuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site personnel .
xEnsuring that protocol deviations are documen ted with corrective action plans, as 
applicable .
xEnsuring that the clinical site has sufficient test article and supplies .
xClarifying questions regarding the study .
xResolving study issues or problems that may arise .
CR-6478, v1.0 
Page 55 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xReviewing of study records a nd source documentation verif ication in accordance with 
the monitoring plan .
18.ETHICAL AND REGULATORY ASPECTS  
18.1. Study -Specific Design Considerations  
Potential s ubjects will be fully informed of the risk s and requirements of the study and, during 
the study, subjects will be given any new information that may  affect their decision to continue 
participation. Subjects will be told that their consent to participate in the study is voluntary and 
may be withdrawn at any time with no reason give n and without penalty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the fully able to 
understand the risks , benefits, and potenti al adverse events of the study and provide their 
consent voluntarily.
18.2. Investigator Responsibility  
The Principal Investigator is responsible for ensuring that the clinical study is performed in 
accordance with the signed agreement, the investigational plan, section 4 of the ICH E6 (R2)
guidelines on Good Clinical Practice (GCP) ,2and applicable regulatory requirements. GCP is 
an international ethical and scientific quality  standard for designing, conducting, recording, 
and reporting studies that in volve the participation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well -being of study subjects are 
protected, consistent with the principles of the Declaration of Helsinki 64th WMA General 
Assembly 20133 and that the clinical study data are cr edible. The Investigator must maintain 
clinical study files in accordance with section 8 of  the ICH E6 (R2) guidelines on Good Clinical 
Practice (GCP) ,2and applicable regulatory requirements.
18.3. Independent Ethics Committee or Institutional R eview Board (IEC/IRB)  
Before the start of the study, the Investigator (o r Sponsor when applicable) will provide the 
IEC/IRB with current and complete copies of  the following documents (where applicable):
xFinal protocol .
xSponsor -approved informed consent fo rm (and any other written materials to be 
provided to the subjects)
xInvestigator’s Brochure (or equivalent information) .
xSponsor -approved subject recruitment materials .
xInformation on compensation for study -related injuries or payment to subjects for 
participation in the study .
xInvestigator’s curriculum vitae, clinical licenses, or equivalent information (unless not 
required, as documented by IEC/IRB) .
xInformation regarding funding, name of the S ponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for subjects .
xAny other documents that the IEC/IRB requests to fulfill its obligation .
CR-6478, v1.0 
Page 56 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
This study will be undertaken only after IEC/ IRB has given full approval of the final protocol,
the informed consent form, applicable recruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly identify the documents being approved.
During the study, the Investigator (or Spo nsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:
xProtocol revisions
xRevision(s) to informed consen t form and any other written materials to be provided to 
subjects
xIf applicable, new o r revised subject recruitment materials approved by the Sponsor
xRevisions to compensation for study -related injuries or payment to subjects for 
participation in the study
xInvestigator’s Brochure revisions
xSummaries of the status of the study (at least ann ually or at intervals stipulated in 
guidelines of the IEC/IRB)
xReports of adverse events that are serious, unanticipated, and asso ciated with the test 
articles, according to the IRB’s requirements
xNew information that may adversel y affect the safety of the subjects or the conduct of 
the study
xMajor protocol deviations as required by the IEC/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Investigator is res ponsible for the study at the clinical site
xAny other requirements of the IEC/IRB
For protocol revisions that increase subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to  the IEC/IRB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this notification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consent  
Each subject or their representative, must give written consent according to local requirements 
after the nature of the stu dy has been fully explained. The c onsent form must be signed before 
performance of any study -related activity. The consent form that is used must be approved by 
both the Sponsor and by the reviewing IEC/IRB. The informed consent is in accordance with 
princ iples that originated in the Declaration of Helsinki,3current ICH GCP2and ISO 
1415 5:20201guidelines, applicable regulatory requirements, and Sponsor Policy.
CR-6478, v1.0 
Page 57 of 140
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to poten tial subject the aims, methods, re asonably anticipated benefits, 
and potential hazards of the study, and any discom fort it may entail. Subjects will be informed 
that their participation is voluntary and that th ey may withdraw consent to participate at any 
time. 
The subject will be given sufficient time to re ad the informed consent form and the opportunity 
to ask questions. After this explanation and be fore entry into the study, consent should be 
appropriately recorded by means of the subject's dated signa ture. After having obtained the 
consent, a copy of the informed consent form must be given to the subject.
18.5. Privacy of Personal Data  
The collection, processing and disclosure of pe rsonal data and medical information related to 
the Study Subject, and persona l data related to Principal Investigator and any clinical site 
personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portability and A ccountability Act (HIPAA) in the 
United States5and other applicable personal data protecti on and security laws and regulations. 
Appropriate measures will be employed to safeguar dthese data, to maintain the confid entiality 
of the person’s related health and medical information, to properly inform the concerned 
persons about the collection and processing of th eir personal data, to grant them reasonable 
access to their personal data and to prevent access by unauthori zed persons.
All information obtained during the course of the invest igation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by Investigators, 
monitors, Sponsor’s personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subjec t concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their 
investigation related activities th at, as part of the investigation will have access to the CRFs 
and subject records.
The collection and processing of pers onal data from subjects enro lled in this study will be 
limited to those data that are necessary to investigate the efficacy, safety, qu ality, and utility of 
the investigational product(s) used in this study.
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations.
The Sponso r ensures that the personal data will be:
xprocessed fairly and lawfully .
xcollected for specified, explicit, and legiti mate purposes and not further processed in a 
way incompatible with these purposes .
xadequate, relevant, and not excessive in relation to said purposes .
xaccurate and, where necessary, kept current .
Page 58 of 140
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such cons ent should also address the transfer of the data to 
other entities and to other countries.
The subject has the right to request through the Investigator access to his personal data and the 
right to request rectificati on of any data that are not correc t or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations.
Appropriate technical and organizational meas ures to protect the personal data against 
unauthorized di sclosures or access, accidental or unlaw ful destruction, or accidental loss or 
alteration must be put in place. Sponsor pers onnel whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential .
19.STUDY RECORD  RETENTION  
In compliance with the ICH GCP guidelines ,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the data collected from each su bject, as well as all 
study documents as specified in ICH GCP2and all study documents as specified by the 
applicable re gulatory requirement(s). The Investigator/Institution will take measures to prevent 
accidental or premature destruction of these documents.
Essential documents must be retained until at least two ( 2)years after the last approval of a 
marketing applicatio n in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical developmen t of the investigational product. These 
documents will be retained for a longer period if required by the applicable regulatory 
requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained .
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custo dy must be transferred to a person who will 
accept the responsibility. The Spons or must be notified in writing of the name and address of 
the new custodian.  Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.
If it becomes necessary for the Sponsor or the appropriate regu latory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.
If the Investigator has a question regarding re tention of study records, he/she should contact 
JJVC.
Page 59 of 140
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
20.FINANCIAL CONSIDERATIONS  
Remuner ation for study services and expenses will be set forth in detail in the Clinical Research 
Agreement. The Research Agree ment will be signed by the Principal Investigator and a JJVC 
management representative prior to study initiation.
JJVC reserves the rig ht to withhold remuneration for costs associated with protocol violations 
such as:
xContinuing an ineligible subject in the study .
xScheduling a study visit outside the subject’s acceptable visit range .
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:
xQuery resolution .
xCase Report Form signature .
xCompletion of any follow -up action items .
21.PUBLICATION  
There is no plan to externally publish t he result sof this investigation.
22.REFERENCES  
1.ISO 14155:20 20: Clinical Investigation of Medical Devices for Human Subjects —
Good Clinical Practice. Available at: https://www.iso.org/standard/71690.html
2.International Council for Harmonization Good Clinical Practice E 6(R2) (ICH GCP). 
Available at: https://www.ich.org/page/efficacy -guidelines
3.Declaration of Helsinki -Ethical principles for Medical Research Involving Human 
Subjects. Available at: https://www.wma.net/policies -post/wma -declaration -of-
helsinki -ethical -principles -for-medical -research -involving -human -subjects/
4.United States (US) Code of Federal Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collecti onCfr.action?collectionCode=CFR
5.Health Information Portability and Accountability Act (HIPA A). Available at: 
https://www.hhs.gov/hipaa/for -professionals/privacy/index.html
 
Page 60 of 140
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
Page 61 of 140
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
Page 62 of 140
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
Page 64 of 140
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
Page 65 of 140
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
Page 66 of 140
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
Page 68 of 140
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
Page 70 of 140
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
Page 71 of 140
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE   
A Patient Instruction Guide (PIG) will be provided separately.
Page 72 of 140
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
Alcon PRECISION1®(VEROFILCON A) FOR ASTIGMATISM Soft Contact Lenses
COOPERVISION MyDay®(stenfilcon A) Toric SOFT CONTACT LENSES
Page 73 of 140
Part Number :PI01100 Page 1of 3
Revision: C Revision Date: June 2021CooperVision MyDay
Soft (Hydrophilic) Daily Disposable
Contact Lenses
IMPORTANT: Please read carefully and keep this information for futur e 
use. This package insert is intended for the Eye Care Practitioner but 
should be made available to patients upon request. The Eye Care 
Practitioner should provide the patient with the patient instructions that 
pertain to the patient's prescrbed lens.
SYMBOLS KEY:
The following symbols may appear on the label or carton.
SYMBOL DEFINITION REFERENCE
Caution: Federal (USA) law restricts 
this device to sale by or on the order 
of a licensed practitioner81 FR 38911
Caution / See Instructions for 
WearersBS EN ISO 15223-1
Table 1, Symbol 5.4.4
Use by Date (expiration date)BS EN ISO 15223-1
Table 1, Symbol 5.1.4
Batch CodeBS EN ISO 15223-1
Table 1, Symbol 5.1 5
Sterile using Steam HeatBS EN ISO 15223-1
Table 1, Symbol 5.2 5
ManufacturerBS EN ISO 15223-1
Table 1, Symbol 5.1.1
Authorized representative in the 
European CommunityBS EN ISO 15223-1
Table 1, Symbol 5.1 2
Do not use if package is damagedBS EN ISO 15223- 1
Table 1, Symbol 5.2 8
Consult instructions for use / consult 
electronic instructions for useBS EN ISO 15223-1
Table 1, Symbol 5.4 3
Do not re-useBS EN ISO 15223-1
Table 1, Symbol 5.4 2
Date of manufactureBS EN ISO 15223-1
Table 1, Symbol 5.1 3
CAUTION: FEDERAL LAW RESTRICTS THIS DEVICE TO SALE BY 
OR ON THE ORDER OF A LICENSED PRACTITIONER.
DESCRIPTIONMyDay Contact Lenses are available as Asphere, Toric, Multifocal , and 
Multifocal Toric lens designs.
The MyDay material stenfilcon A is primarily a random copolymer of 
polydimethylsiloxane methacrylateand vinylmethyl acetamide. The UV 
blocker used is a benzotriazolyl methacrylate. The lenses have a blue 
tint which is added to make the lens more visible for handling. The 
lenses also contain a UV absorbing monomer which is used to block 
UV radiation.
WARNING: UV-absorbing contact len ses are NOT substitutes for 
protective UV-absorbing eyewear such as UV-absorbing goggles 
or sungl asses because they do not completely cover the eye and 
the surrounding area. You should continue to use UV-absorbing 
eyewear as directed.
Long term exposure to the UV radiation is one of the risk factors 
associated with cataracts. Exposure is based on a number of 
factors such as environmental conditions (altitude, geography, 
cloud cover) and personal factors (extent and nature of the 
outdoor activities). UV-absorbing contact len ses help provide 
protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-absorbing 
contact lenses reduces the risk of developing cataracts or other 
eye disorders. Consult your Eye Care Practitioner for more 
information.The MyDay (stenfilcon A) Soft (Hydrophilic) Contact Lens (-6.00 D) 
blocks 86% of UVA radiation and 97% UVB radiation average 
across the spectrum. The radiation blockage of the MyDay 
(stenfilcon A) lens will increase for thicker lenses (please refer to 
accompanying transmittance curve graph).
1. Leman, S., Radiant Energy and the Eye , MacMillan, New York, 1980,
p. 58, figure 2-21. Transmittance profile of the human cornea of a 24-
year-old person.
2. Waxler M., and V. M. Hitchins, Optical Radiation and Visual Health ,
CRC Press, Boca Ra ton, Florida , 1986, p. 19, figure 5. Transmittance 
profile for the human crystalline lens of a 25-year-old person.
MyDay (stenfilcon A) contact lens parameters:
oChord Diameter: 13.0 mm to 15.5mm
oBase Curve: 8.4 ± 0.5 mm and 8.7 ± 0.5 mm
oCenter Thickness: 0.08 mm @ -3.00D (varies with power)
oPowers: -20.00D to +20.00D
oCylinder Powers: -0.25D to -10.00D
oAxis: 0oto 180oin 10oincrements
oAdd Power Range: +0.50D to +4.00D
oMultifocal Add Power Range: LOW = (+0.75Dto +1.25D)
MED = (+1.50D to +1.75D)
HIGH = (+2.00D to +2.50D)
The physical/optical properties of the lens are:
oSpecific Gravity: 1.033
oRefractive Index: 1.401
oLight Transmittance: 96%
oSurface Character: Hydrophilic
oWater Content: 54%
oOxygen Permeability: 80x10-11
[(cm2/sec)x(ml O 2)/(ml x mm Hg)]
Call our Customer Service Department at (800) 341-2020
for current availability.
ACTIONS
When placed on the cornea in its hydrated state, the MyDay Soft 
(Hydrophilic) Contact Lens acts as a refracting medium to focus light 
rays on the retina. 
INDICATIONS FOR USE
Aspherical:
MyDay (stenfilcon A) ASPHERE Soft Contact lenses are indicated for 
the correction of ametropia (myopia and hyperopia) in aphakic and 
non-aphakic persons with non-diseased eyes in powers from -20.00D 
to +20.00D diopters. The lenses may be worn by persons who exhibit 
astigmatismof -2.00 diopters or less that does not interfere with visual 
acuity.
Page 76 of 140
Part Number :PI01100 Page 2of 3
Revision: C Revision Date: June 2021Toric:
MyDay (stenfilcon A) TORIC Soft Contact lenses are indicated for the 
correction of ametropia (myopia or hyperopia with astigmatism) in 
aphakic and non-aphakic persons with non-diseased eyes in powers 
from -20.00 to +20.00 diopters and astigmatic corrections from -0.25 to 
-10.00 diopters.
Multifocal:
MyDay (stenfilcon A) MULTIFOCAL Soft Contact lenses are indicated 
for the correction of refractive ametropia (myopia and hyperopia) and 
emmetropia with presbyopia in aphakic and non-aphakic persons with 
non-diseased eyes. The lenses may be worn by persons who exh bit 
astigmatism of -2.00 diopters or less that does not interfere with visual 
acuity.
Multifocal Toric:
MyDay (stenfilcon A) MULTIFOCAL TORIC Soft Contact lenses are 
indicated for the optical correction of distance and near vision in 
presbyopic phakic or aphakic persons with non-dieseased eyes who 
may have -10.00 diopters of astigmatism or less.
CONTRAINDICATIONS (REASONS NOT TO USE) :
Do not use the MyDay lens when any of the following conditions exist:
oAcute and subacute inflammation or infection of the anterior 
chamber of the eye.
oAny eye disease, injury, or abnormality that affects the cornea, 
conjunctiva, or eyelids.
oSevere insufficiency of lacrimal secretion (dry eyes).
oCorneal hypoesthesia (reduced corneal sensitivity), if not aphakic .
oAny systemic disease that may affect the eye or be exaggerated 
by wearing contact lenses.
oAllergic reactions of ocular surfaces or adnexa that may be 
induced or exaggeratedby wearing contact lenses.
oAny active corneal infection (bacterial, fungal, or viral).
oIf eyes become red or irritated.
oThe patient is unable to follow lens care regimen or unable to 
obtain assistance to do so.
WARNINGS
Patients should be advised of the following warnings 
pertaining to contact lens wear:
oPROBLEMS WITH CONTACT LENSES AND LENS CARE 
PRODUCTS COULD RESULT IN SERIOUS INJURY TO THE 
EYE. It is essential that patients follow their Eye Care 
Practitioner’s directions and all labeling instructions for proper 
use of lenses. Eye problems, including corneal ulcers, can 
develop rapidly and lead to loss of vision .Daily wear lenses 
are not indicated for overnight wear, and patients shou ld be 
instructed not to wear lenses while sleeping. Clinical studies 
have shown that the risk of serious adverse reactions is 
increased when these lenses are worn overnight. Studies have 
shown that contact lens wearers who are smokers have a 
higher incidence of adverse reactions than nonsmokers. If a 
patient experiences eye discomfort, excessive tearing, vision 
changes, or redness of the eye, the patient should be 
instructed to immediately remove lenses and promptly contact 
his or her Eye Care Practitioner.
PRECAUTIONS
Special Precautions for Eye Care Practitioners
o Due to the small numbers of patients enrolled in clinical 
investigation of lenses, all refractive powers, design 
configurations, or lens parameters available in the lens material 
are not evaluated in significant numbers. Consequently, when 
selecting an appropriate lens design and parameters, the Eye Care Practitioner should consider all characteristics of the lens that can affect lens performance and ocular health, including 
oxygen permeability, wettability, central and peripheral thickness, 
and optic zone diameter.
o The potential impact of these factors on the patient’s ocular heal th 
should be carefully weighed against the patient’s need for 
refractive correction; therefore, the continuing ocular health of the 
patient and lens performance on the eye should be carefully 
monitored by the prescrbing Eye Care Practitioner.
o Patients who wear aspheric contact lenses to correct presbyopia 
may not achieve the best corrected visual acuity for either far or 
near vision. Visual requirements vary with the individual and 
should be considered when selecting the most appropriate type of 
lens for each patient.
o Aphakic patients should not be fitted with any MyDay contact 
lenses until the determination is made that the eye has healed 
completely.
o Fluorescein, a yellow dye, should not be used while the lenses 
are on the eyes. The lenses absorb the dye and become 
discolored. Whenever fluorescein is used in the eyes, the eyes 
should be flushed with a sterile saline solution that is 
recommended for in-eye use.
o Before leaving the Eye Care P ractitioner’s office, the patient 
should be able to promptly remove the lenses or should have 
someone else available who can remove the lenses for him or 
her. Eye Care Practitioners should instruct the patient to remove 
the lenses immediately if the eye becomes red or irritated.
Eye Care Practitioners should carefully instruct patients about the 
following safety precautions:
o Always discard disposable lenses after the recommended 
wearing schedule prescrbed by the Eye Care Practitioner.
o The compatibility of the lens with lens care regimens has not been
evaluated. 
o Do not use saliva or any solutions for lubricating or wetting 
lenses.
o If the lens sticks (stops moving) on the eye, follow the 
recommended directions on Care for a Sticking Lens. The lens 
should move freely on the eye for the continued health of the ey e. 
If non-movement of the lens continues, the patient should be 
instructed to immediately consult his or her Eye Care 
Practitioner.
o Always wash and rinse hands before handling lenses. Do not get 
cosmetics, lotions, soaps, creams, deodorant, or sprays in the 
eyes or on the lenses. It is best to put on lenses before putting on 
makeup. Water-based cosmetics are less likely to damage lenses 
than oil-based products.
o Do not touch the contact lenses with the finger or hands if the 
hands are not free of foreign materials, as lens damage may 
occur.
o Carefully follow the handling, insertion, removal, and wearing 
instructions in the Patient Instructions for MyDay contact lenses 
and those prescrbed by the Eye Care Practitioner.
o Never wear lenses beyond the period recommended by the Eye 
Care Practitioner.
o If aerosol products such as hairspray are used while wearing 
lenses, exercise caution and keep eyes closed until the spray has 
settled.
o Always handle lenses gently and avoid dropping them.
o Avoid all harmful or irritating vapors and fumes while wearing 
lenses.
o Ask the Eye Care Practitioner about wearing the lenses during 
sporting activities.
o Inform the doctor (health care practitioner) about being a contact 
lens wearer.
o Never use tweezers or other tools to remove lenses from the lens container unless specifically indicated for that use. Pour the lens 
into your hand.
o D
o not touch the lens with fingernails.
o Always contact the Eye Care Practitioner before using any medicine in the eyes.
Page 77 of 140
Part Number :PI01100 Page 3of 3
Revision: C Revision Date: June 2021o Always inform the employer of being a contact lens wearer. Som e 
jobs may require use of eye protection equipment or may require 
that the patient not wear contact lenses.
o As with any contact lens, follow-up visits are necessary to assure the continuing health of the patient’s eyes. The patient should be 
instructed as to a recommended follow-up schedule.
ADVERSE REACTIONS
The patient should be informed that the following problems may occur:
o Eyes stinging, burning, or itching (irritation), or other eye pain.
o Comfort is less than when the lens was first placed on the eye.
o Feeling that something is in the eye such as a foreign body or a 
scratched area.
o Excessive watering (tearing) of the eyes.
o Unusual eye secretions.
o Redness of the eyes.
o Reduced sharpness of vision (poor visual acuity).
o Blurred vision, rainbows, or halos around objects.
o Sensitivity to light (photophobia).
o Dry eyes.
If the patient notices any of the above, he or she should be instructed 
to:
o Immediately remove the lenses.
o If the discomfort or the problem stops, then look closely at the 
lens. If the lens is in some way damaged, do not put the lens bac k 
on the eye. Place the lens in a storage case and contact the Eye 
Care Practitioner. Daily disposible lenses should not be 
reinserted. If the problem continues, the patient should 
immediately remove the lenses and consult the Eye Care 
Practitioner .
When any of the above problems occur, a serious condition such as 
infection, corneal ulcer, neovascularization, or iritis may be present. 
The patient should be instructed to keep the lens off the eye and 
seek immediate professional identification of the problem and prompt 
treatment to avoid serious eye damage.
FITTING
Conventional methods of fitting contact lenses apply to all MyDay 
contact lenses. For a detailed description of the fitting techniques, refer 
to the MyDay Professional Fitting and Information Guide, copies of 
which are available from:
CooperVision, Inc.
711 North Road
Scottsville, New York 14546
(800) 341-2020
www.c oopervision.com
WEARING SCHEDULE
The wearing schedule should be determined by the Eye Care 
Practitioner. Patients tend to over-wear the lenses initially. The Eye 
Care Practitioner should emphasize the importance of adhering to the 
initial maximum wearing schedule. Regular checkups, as determined 
by the Eye Care Practitioner are also extremely important.
CooperVision recommends that all MyDay lenses be discarded and 
replaced with a new lens on a daily basis. DAILY DISPOSABLE WEAR: (less than 24 hours, while awake). 
The maximum suggested wearing time is 12 hours:
LENS CARE DIRECTIONS
The MyDay (stenfilcon A) Soft (Hydrophilic) Contact Lenses are 
indicated for daily wear single use only. The lenses are to be discarded 
upon removal; therefore, no cleaning or disinfection is required.
For MyDay contact lenses prescribed for daily wear single use only:
The Eye Care Professional should review with patients that no 
cleaning or disinfection is needed. Patients should always dispose of lenses when they are removed and have replacement lenses or 
spectacles available.
Eye Care Practitioners should review with the patient lens care 
directions, including basic lens care information in accordance with 
patients lens type and wearing schedule.
o Always wash, rinse, and dry hands before handling contact 
lenses.
o Do not use saliva or any solutions for lubricating or rewetting. Do 
not put lenses in the mouth.
o The patient should always have a spare pair of lenses at all times.
o Eye Care Practitioners may recommend a lubrication/rewetting 
solution, which can be used to wet (lubricate) the lenses while 
they are being worn to make them more comfortable.
CARE FOR A DRIED OUT (DEHYDRATED) LENS
If any MyDay lens is exposed to air while off the eye, it may become 
dry and brittle. In this event, simply dispose of the lens and replace 
with a fresh one.
CARE FOR A STICKING (NONMOVING) LENS
If the lens sticks (stops moving or cannot be removed), the patient 
should be instructed to apply 2 to 3 drops of the recommended 
lubricating or rewetting solution directly to the eye and wait until the 
lens begins to move freely on the eye before removing it. If non-
movement of the lens continues more than 5 minutes, the patient 
should immediately consult the Eye Care Practitioner.
EMERGENCIES
The patient should be informed that if chemicals of any kind 
(household products, gardening solutions, laboratory chemicals, etc.) 
are splashed into the eyes, the patient should: FLUSH THE EYES 
IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT 
THE EYE CARE PRACTITIONER OR VISIT A HOSPITAL 
EMERGENCY ROOM WITHOUT DELAY.
HOW SUPPLIED
Each lens is supplied sterile in a blister containing buffered saline 
solution. The blisteris labeled with the base curve, diameter, dioptric 
power, cylinder and axis for toric lenses, multifocal add for multifocal 
lenses, manufacturing lot number, andexpiration date of the lens, and 
the presence of a UV-blocker is noted.
DO NOT USE IF THE BLISTER IS BROKEN OR 
THE SEAL HAS BEEN DAMAGED
REPORTING OF ADVERSE REACTIONS
All serious adverse experiences and adverse reactions observed in 
patients wearing any MyDay contact lens or experienced with the 
lenses should be reported to:
CooperVision, Inc.
Attn: Product Services
711 North Road
Scottsville, New York 14546
(800) 341-2020
www.co opervision.com
Page 78 of 140
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX D:   
x LENS FITTING CHARACTERISTICS
x  SUBJECT REPORTED OCULAR SYMPTOMS
x  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS 
x  BIOMICROSCOPY SCALE 
x  DISTANCE AND NEAR VISUAL ACUITY EVALUATION 
x TORIC FIT EVALUATION
x ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE
x  PATIENT REPORTED OUTCOMES
x  LENS INSERTION AND REMOVAL
x VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING
CR-6478, v1.0 
Page 79 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 LENS FITTING CHARACTERISTICS  
CR-6478, v1.0 
Page 80 of 140JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 1of 5CR-6478, v1.0 
Page 81 of 140JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 2of 5CR-6478, v1.0 
Page 82 of 140JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 3of 5CR-6478, v1.0 
Page 83 of 140JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 4of 5CR-6478, v1.0 
Page 84 of 140JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 5of 5CR-6478, v1.0 
Page 85 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SUBJECT REPORTED OCULAR SYMPTOMS  
CR-6478, v1.0 
Page 86 of 140JJVC CONFIDENTIAL
Title:                         Subject Reported Ocular Symptoms/Problems
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 1CR-6478, v1.0 
Page 87 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
CR-6478, v1.0 
Page 88 of 140JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 1of 5CR-6478, v1.0 
Page 89 of 140JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 5CR-6478, v1.0 
Page 90 of 140JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 5CR-6478, v1.0 
Page 91 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 BIOMICROSCOPY SCALE  
CR-6478, v1.0 
Page 94 of 140JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6478, v1.0 
Page 95 of 140JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6478, v1.0 
Page 96 of 140JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6478, v1.0 
Page 97 of 140JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6478, v1.0 
Page 98 of 140JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6478, v1.0 
Page 99 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
CR-6478, v1.0 
Page 100 of 140JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 4CR-6478, v1.0 
Page 102 of 140JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 4CR-6478, v1.0 
Page 103 of 140JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 4CR-6478, v1.0 
Page 104 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TORIC FIT EVALUATION  
CR-6478, v1.0 
Page 105 of 140JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 1of 4CR-6478, v1.0 
Page 106 of 140JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 2of 4CR-6478, v1.0 
Page 107 of 140JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 3of 4CR-6478, v1.0 
Page 108 of 140JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 4of 4CR-6478, v1.0 
Page 109 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 ETDRS DISTANCE VISUAL ACUITY MEASUREMENT PROCEDURE  
CR-6478, v1.0 
Page 110 of 140JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 5 
 
 CR-6478, v1.0 
Page 112 of 140JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 5 
 CR-6478, v1.0 
Page 113 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 PATIENT REPORTED OUTCOMES  
CR-6478, v1.0 
Page 114 of 140JJVC CONFIDENTIAL
Title: Patient Reported Outcomes
Document Type:
Document Number: Revision Number: 3
Page 1of 1
CR-6478, v1.0 
Page 115 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
LENS INSERTION AND REMOVAL  
CR-6478, v1.0 
Page 116 of 140JJVC CONFIDENTIAL
Title:   Lens Insertion and Removal
Document Type:
Document Number : Revi sion Number:  3
Page 1of 2CR-6478, v1.0 
Page 117 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 VISUAL ACUITY CHART LUMINANC E AND ROOM ILLUMINATION 
TESTING  
CR-6478, v1.0 
Page 119 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 8CR-6478, v1.0 
Page 120 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 8CR-6478, v1.0 
Page 121 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 8CR-6478, v1.0 
Page 122 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 8CR-6478, v1.0 
Page 123 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 5of 8CR-6478, v1.0 
Page 124 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 6of 8CR-6478, v1.0 
Page 125 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 7of 8CR-6478, v1.0 
Page 126 of 140JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 8of 8CR-6478, v1.0 
Page 127 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX E:  GUIDELINES FOR COVID -19 RISK MITIGATION  
CR-6478, v1.0 
Page 128 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
1.0 PURPOSE
The purpose of this doc ument is to provide guidelines for the re -opening or initiation of clinical study sites 
participating in Johnson &Johnson Vision Care, Inc. ( JJVCI )clinical studies dur ing the COVID -19
pandemic.
2.0 SCOPE
This document provides guidelines for Johnson &Johnson Vision Care ( JJVCI )to address the potential risks 
from COVID -19 to study subjects ,investigators, study site staff, and monitors at study sites.The guidance 
provided in this document is in effect from the date of approval through th e date of retirement of this Work 
Instruction. At a minimum ,this Work Instruction will be  reviewed and updated on a quarterly basis, a s
appropriate.
NOTE:  Re-opening of s ites outside of the US will be evaluated on a country by country basis subject 
to local health authority guidance.
3.0 DEFINITIONS
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, Flor ida. Its goal is to maintain and enhance excellence in optometric 
practice, by both promoting research and the di ssemination of knowledge. The AAO holds an annual 
meeting, publishes a monthly scientific journal, give s credentials to optometrists  through the fellowship 
process and publishes position statements.
American Optometric Association ( AOA ):The American Optom etric Association, founded in 1898, is 
the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 
Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take 
a leading role in patient care with respect to eye and vision care, as well as general health and well -being. 
As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, 
diagnose, treat and manage ocular disorders, diseas es and injuries and sys temic diseases that manifes t in the 
eye. The American Optometric Asso ciation is a federation of state, stud ent, and armed forces optometric 
associations. Through these affiliations, the AOA serves me mbers consisting of optometrists, students of 
optometry, paraoptometric assistants a nd technicians. The AOA and its aff iliates work to provide the public 
with quality vision and eye care.
Center sfor Disease Control and Prevention (CDC ):The Centers for Disease Control and Prevention is a 
national public health institute in the United States. It is a United States federal agency, under the 
Department of Health and Human Services, and is headquartered in Atlanta, Georgia.
COVID -19: Current outbreak of respiratory  disease caused by a novel coronavirus. The virus has been 
named “S ARS -CoV -2” and the disease it causes has been  named “Coronavirus Disease 2019” (COVID -
19).
Clinical Study: Voluntary research studies cond ucted in people and designed to answer specific questions 
about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing 
treatments. May also be called clinical trials, studies, research, trials, or protocols.
Clinical Study Site: Location where a clinical study is  conducted, such as a doctor’s office, university, or 
laboratory. Clin ical studies are conducted by Investigators who are individual(s) responsible for the 
conduct of the clinical study at a study site. If a stud y is conducted by a team of individuals, the 
Investigator is the responsible leader  of the team and may be called the Principal Investigator.
Clinical Operations Manager (COM) :The Johnson & Johnson Vision Care ( JJVC I) individual 
responsible for the overall ma nagement of a clinical trial.
CR-6478, v1.0 
Page 129 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Monitor: Anindividual designated to oversee the progress of a clinical study and ensure that it is 
conducted, recorded, and reported in accordance with  the protocol, Standard Operating Procedures (SOPs), 
Good Clinical Practice (GCP), and ap plicable regulatory requirements.
Medical Safety Officer (MSO) :Physician who has prim ary accountability in their product portfolio for 
product health and safety, and who serves as an independent medical voice for patient safety.
Safety Management Team (SMT) :A cross -functional, collaborative team responsible for review, 
assessment and eva luation of medical safety data arising from any source throughout the product life cycle.
4.0 GUIDANCE FOR STUDY DOCUMENTS
In alignment with recent health authorit yguidance, JJVCI is providing recommendations for study -related 
management in the event of disruption to the conduct of the clinical study. This guidance does not supersede 
any local or government requirements or the clinical judgement of  the investigator to protect the health ,safety
and well -being of particip ants and site staff. If, at an y time, a participant’s safety is considered to be at risk, 
study intervention will be discontinued, and study follow -up will be conducted as outlined in the protocol.  
During the COVID -19 pandemic, the additional risks liste d below need to be considered for study participants 
and study personnel :
Additional Risks Related to the COVID -19 Pandemic:
xThe p ossible transmission of the Coronavi rusinfection and consequent complications, beyond the 
risk of adverse events due to the investigational device and/or procedures .
xThe risk may be higher in an op tometric clinical study because of the close contact the subject will 
have with health care professionals during the proce dures and assessments (since the investigator
must make the measurements close to the subject’s face) and, in addition the need for multiple 
follow -up visits/exams which may expose the subject to other patients and/or healthcare 
professionals who might be transmitting the virus ,even if they do not have symptoms.
xPotential disruptions to the study may be nece ssary due to current or future pandemic -related 
emergency restrictions, which may lead to delays in scheduled follow -up visits.
xSubjects experienc ingan adverse event related to contact lens wear may receive delayed treatment 
due to COVID -19restrictions. In this event, a ll assessments that can be conducted virtually will be 
completed by the investigator to determine the best course of treatment for the subject, including
anunscheduled visit, up to discontinuation from the study , as appropriate .
Ifastudy subject is found to  have contracted COVID -19during participation in astudy, he/she will be 
discontinued from the study and follo wed until COVID -19Adverse Event (AE) resolution.
To help minimize the above potential risks, JJVCI recommend reviewing/complying with local, state, 
and governmental guidance for COVID -19 risks. 
JJVC Iwill provide the following study specific documents wi th language pertaining to COVID -19 risks:
4.1.1 Informed Consent :
Will include information concerning the study -associated risks relate d to the COVID -19 pandemic 
in bold font and/or boxed on the first page of the I nformed Consent document:
CR-6478, v1.0 
Page 130 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS ) PANDEMIC
It is important to note that this  study will be conducted, at leas t in part, during the COVID -19 pandemic. As such, 
additional risks associated with  the infection with COVID -19 exist for you. Thi s is particularly important for this 
study due, in part, to the closeness of the doctor during the study examinations. 
The potential effects of the dise ase are not fully known, at th is time, and may include long -term serious health 
consequences. In sever e cases, this may result in hospitalization and/or death. Based on current knowledge from the 
Center sfor Disease Control and Prevention (CDC), those at high -risk for severe illness from COVID -19 include 
older adults and people w ith underlying medical cond itions. 
During this study, all appropriate measur es will be taken to minimize risks in cluding the use of personal protective 
equipment such as masks and glov es, as well as proper sanitization. This is in conformance to guidance from the 
CDC, local healt h departments, and the state and county in which the study doctor’s office  is located. However, 
these measures may not completely eliminate th e risks associated with contracting COVID -19. 
If you are found to have contracted COVID -19 or feel ill with flu -like symptoms during pa rticipation in the study, 
you will not be permitted to continue in -office study follow -up visits ,but you will receive instructions and your 
condition will be monitored by the doctor and/or study staff.
4.1.2 COVID -19 Risk Control Check list(Attachment -B):
Will include COVID -19 risk control methods that are required by a site to conduct JJVCI clinical 
studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Princip al
Investigator will review/sign the study specific  checklist prior to the Site Initiation Meeting.
4.1.3 Protocol Compliance Investigator(s) Signature Page :
Will include a statement indicating thatthePrincipal Investigator ( PI)agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s for COVID -19 risk mitigation. 
I have read the sugges ted guidance provided by JJVCI pertaining to the COVID -19 risk mitigation,
(COVID -19 Work Instruction in the Appendix of this protocol) .I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.
4.1.4 Study Site Initiation Training Slides :
Will include sug gestions to help mitigate potential transmission of COVID -19. Suggestions may 
include maintaining social distan cing in the clinical site by staggered scheduling of study p atients,
wearing proper PPEs, frequ ent disinfection, and installing shields on the s lit lamp and other 
applicable equipment .
5.0 GUIDANCE FOR REMOTE SUBJECT VISITS
Potential disruptions to the study may be nece ssary due to current or future pandemic -related emergency 
restrictions .  Possible disruption of the study as a result of COVID -19 control measures may lead to delays 
in scheduled follow -up visits.
Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID -19 control 
measures or due to the subj ect’s concerns or fears about COVID -19risk.When appropriate , the remote 
assessment willbe conducted to the extent possible.  Discussions with the subject during remote assessments 
may include:
CR-6478, v1.0 
Page 131 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
The sponsor will contin ue to monitor the co nduct and progress of the clinical study, and any changes will be 
communicated to the sites and to the health authorities ac cording to local guidance.
 
If a participant has tested positive for COVID -19, the investigator should co ntact the sponsor’s responsible 
medical monitor to discuss initial plan s for study intervention and follow -up. The medical monitor will 
notify the Safety Management Team of a ny subject(s) that have reported “COVID -19”, “ Asymptomatic 
COVID -19”, or “Suspected COVID -19” adverse events within 24 hours of the notification. 
Modifications made to the study c onduct as a result of the COVID -19 pandemic will be summarized in the 
clinical study report.  
COVID -19 screening procedur es that may be mandated by lo cal healthcare systems do not need to be 
reported as an amendment to the protocol even if done during clinical study visits.
Monitoring Visits
When on -site monitoring by the sponsor is not feasible ,the sponsor’s site monitor w ill contact the study 
site to schedule remote visits. In such cases, on -site monitoring visits will resume when feasible, with
increased frequency to address th e source data verification backlog.
Even with staffing lim itations during this COVID -19 pandemic , all routine operations related to clinical 
trials should be well -documented and archived as pa rt of standard process. When conditions permit, all 
parties involved in this clinical  trial should communicate relevant information in a timely  manner so that 
all relevant parties remain  sufficiently informed.
6.1.1 Study Site Initiation:  
During the period that this Work Instruction is in effect , Site Initiation Meetings and training of 
study site staff will be conducted remotely .The JJVCI study team will conduct tr aining via Skype, 
Zoom, Microsoft Teams or similar software as well as utilize online training materials ,as applicable.  
Study site training will be documented utilizing Site Initiation Report (Form Control No. 
)per Study Site Initiation ( Form Control No. ).
On-site visits may be considered when, for example, hands -on training or evaluation of site facilities 
is required. While on site, the Clinical Research Associate ( CRA )will follow all local, state, and 
governmental policies for COVID -19 Risk Mitigation, including socia l distancing, wearing of PPE, 
etc. as applicable for the lo cation of the study site.
6.1.2 Interim Monitoring Visits (if applicable) :
During the period that this Work Instruction is in effect, Interim Monitoring On-site v isits will be 
kept to a minimum and include only those tasks that the CRA cannot perform remotely (e.g., source 
document verification , test article reconciliation, etc.) .
To ensure data integrity during the conduct of all JJVC studies, clinical study teams will follow the 
study specific Clinical Monitoring Plan (Form Control No. ).
While on site, the CRA will follow all local, state,  and governmental policies for COVID -19 Risk 
Mitigation, including social distancing, wearing of PP E, etc. as applicable for the location of the 
study site.
CR-6478, v1.0 
Page 133 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
6.1.3 Study Site Closure:  
During the period that this Work Instruction is in effect, the durati on of the Study Site Closure Visit 
willbe lim ited to tasks that the CRA cannot perform re motely (e.g., source document verification, 
test article final rec onciliation and return, etc.).  
CR-6478, v1.0 
Page 134 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Attachment A: Study Site Correspondenc e
XXXX XX, 2020
Re: COVID -19 Mitigation Plan, << CR-xxxx /protocol title>>
Dear <<Princip alInvestigator>> and Study Team,
Coronavirus (COVID -19) has impacted several communities and busi ness activities over the past several months. 
While we work toward the successful  conduct of clinical studies, our commitme nt continues to be the safety of 
patients, healthcare professi onals, and to our communities. 
Therefore, we would like to share th e following revisions/additions related to the above referenced Johnson & 
Johnson Vision Care company sponsored clinical tria l(s) you are currently working on or considering participation 
within. 
Protocol:
xGuidelines for COVID -19 Risk Mitigation provided in the Appendix section.
Protocol Signature Page:
xWill include a statement indicating the Princip al Investigator agrees to conduct the study in compliance 
with all local, state, and gove rnmental guidelines for COVID -19 risk mitigation.
Informed Consent:
xWill include information concerning the study -associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent document.
COVID -19 Risk Control Checklist for Clinical Studies:
xWill include COVID -19 risk control measures that ar e required to ensure the saf ety and health of subjects, 
site staff and monitors during the pa ndemic.   
We want to encourage the need for open lines of co mmunication about potential challenges you may foresee as the 
result of the current COVID -19 situation. Therefore, we encourage you  to regularly connect with your respective 
Johnson & Johnson cl inical study team ( Clinical Research Associate ( CRA ),Lead CRA or Study Managers).  
Thank you for your continued engageme nt, collaboration, and dedication to your study subjects during this 
challenging time. 
Please file this letter in your s ite file study correspondence. 
CR-6478, v1.0 
Page 135 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
RESOURCE LINKS
US Resource Links 
xOSHA Training
https://www.osha.gov/SLTC/covid -19/controlprevention.html
Personal Protective Equipment ( PPE)Training
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/using -ppe.html
xI&R Training
ACUVUE®LensAssist: https://www.acuvue.com/lensassist    
xClinic Preparedness Guides
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/clini c-preparedness html
AOA: https://aoa.uberflip.com/i/1240437 -aoa-guidance -for-re-opening -practices -covid·19/1?m4=
American Optom etric Association: https://www.aoa.org/optometry -practice -reactivation -preparedness -
guide
xln-Office Disinfection of Multi -Patient Use Diagnostic Contact Lenses
https://www.gpli.info/wp -content/uploads/2020/03/2020 -01-15-in-office -disinfecting -of-diagnostic -
lenses.pdf
OUS Resource Links 
xUpdates on local regulations in Hong Kong
https://www.coronavirus.gov hk/eng/index.html
xResumption of optical services in England: Letter from Matt Neligan and Poonam Sharma
https://www.england nhs.uk/coronavi rus/wp -content/uploads/sites/52/2020/04/C0601 -reopening -of-optical -
services -letter -17-june-2020.pdf
xNHS Optical Letter
https:/ /www.england nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0127 -optical -letter -1-april-
2020.pdf
xThe College of Opto metrists primary eye care COVID -19 guidance: Red phase
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavirus -covid -19-guidance -
for-optometrists .html
xThe College of Optometrists COVID -19: College updates
https://www.college -optometrists.org/t he-college/media -hub/news -listing/coronavirus -2019 -advice -for-
optometrists.html# CollegeGuidelines
xInfection Control Guidelines. (n .d.). Retrieved from Canadian  Association Of Optometrists: 
https://opto.ca/sites/defau lt/files/resources/docume nts/infection_control_guidelines_2016.pdf
xInfection prevention an d control for COVID -19: Interim guidance for outpatient and ambulatory care 
settings. (2020, May 23 May). Retrieved from Govern ment of Canada: https ://www.canada.ca/en/public -
health/services/ diseases/2019 -novel -coronavirus -infection/guidance -documents/interim -guidance -
outpatient -ambulatory -care-settings html
CR-6478, v1.0 
Page 138 of 140JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
xInformation for Members On Coronavirus (COVID -19). (n.d.). Retrieved from Canadian Association Of
Optometrists: 
https://opto.ca/sites/def ault/files/resources/documents/information_for_members_on_coronavirus.pdf
xCoronavirus (COVID -19) resources for health professionals, in cluding aged care providers, pathology 
providers and health care managers. (2020, September 24). Retrieved from Australian Government 
Department of Health:
https://www health.gov.au/res ources/collections/coronavirus -covid -19-resources -for-health -professionals -
including -aged -care-providers -pathology -providers -and-health -care-managers
 
xEnvironmental Cleaning and Disinfection Principles for COVID -19. (n.d.). Retrieved from Australian 
Government Department of Health: 
https://www.health.gov.au/s ites/default/files/documents /2020/03/environmental -cleaning -and-disinfection -
principles -for-covid -19.pdf
xInfection control guidelines and advice. (n .d.). Retrieved from Optometry Australia : 
https://www.optometry.org.au/practice -professional -support/coronavirus -covid -19-what -optometrists -need -
to-know/covid -19-clinical -advice/infection -control -guideline s-and-advice/
 
CR-6478, v1.0 
Page 139 of 140JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL COMPLIANCE INVEST IGATOR(S) SIGNATURE PAGE  
Protocol Number and Title: CR-6478 Clinical Evaluation of Two Daily Disposable Toric Soft 
Contact Lenses Over One Week of Wear
Version and Date: 1.015 December 2021
I have read and understand the protocol sp ecified above and agree on its content.  
I agree to conduct this study according to ISO 14155 :2020 ,1GCP and ICH guidelines ,2the 
Declara tion of Helsinki ,3United States (US) Code of Federal Regulations (CFR) ,4and the 
pertinent individual country laws/regulations and to comply with its obligations, subject to 
ethical and safety considerations. The Principal Investigator is responsible for ensuring that all 
clinical site personn el, including Sub -Investigators adhere to all ICH2regulations and GCP 
guidelines regarding clinical trials  during and after study completion.
Iwill assure that no deviation from  or changes to the protocol w ill take place without prior 
agreement from the Sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the tria l participants.
I am responsible for ensuring that all clinical site personnel including Sub -Investigators adhere 
to all ICH2regulations and GCP g uidelines regarding clinical trials during and after study 
completion.
All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training. 
I agree to ensure that all clinical site personnel involved in th e conduct of this study are 
informed about their obligations in meeting the above commitments.
I shall not disclose the information contained in this protocol or any results obtained from this 
study without written authorization.
I have read the suggeste d guidance provided by JJVCI pertaining to the COVID -19 risk 
mitigation, (COVID -19 Work Instruction in the Appendix Eof this protocol). I agree to 
conduct this study in compliance with local, state, governmental guidance for COVID -19 risks.
Principal 
Investigator:
Signature Date
Name and Professional Position (Printed)
Institution/Site:
Institution/Site Name
Institution/Site Address
CR-6478, v1.0 
Page 140 of 140JJVC CONFIDENTIAL